,protocolSection_outcomesModule_primaryOutcomes_0_measure,protocolSection_outcomesModule_primaryOutcomes_0_description,protocolSection_outcomesModule_primaryOutcomes_0_timeFrame,protocolSection_outcomesModule_primaryOutcomes_1_measure,protocolSection_outcomesModule_primaryOutcomes_1_description,protocolSection_outcomesModule_primaryOutcomes_1_timeFrame,protocolSection_outcomesModule_primaryOutcomes_2_measure,protocolSection_outcomesModule_primaryOutcomes_2_description,protocolSection_outcomesModule_primaryOutcomes_2_timeFrame,protocolSection_outcomesModule_primaryOutcomes_3_measure,protocolSection_outcomesModule_primaryOutcomes_3_description,protocolSection_outcomesModule_primaryOutcomes_3_timeFrame,protocolSection_outcomesModule_primaryOutcomes_4_measure,protocolSection_outcomesModule_primaryOutcomes_4_description,protocolSection_outcomesModule_primaryOutcomes_4_timeFrame,protocolSection_outcomesModule_primaryOutcomes_5_measure,protocolSection_outcomesModule_primaryOutcomes_5_description,protocolSection_outcomesModule_primaryOutcomes_5_timeFrame,protocolSection_outcomesModule_primaryOutcomes_6_measure,protocolSection_outcomesModule_primaryOutcomes_6_description,protocolSection_outcomesModule_primaryOutcomes_6_timeFrame,protocolSection_outcomesModule_primaryOutcomes_7_measure,protocolSection_outcomesModule_primaryOutcomes_7_description,protocolSection_outcomesModule_primaryOutcomes_7_timeFrame,protocolSection_outcomesModule_primaryOutcomes_8_measure,protocolSection_outcomesModule_primaryOutcomes_8_description,protocolSection_outcomesModule_primaryOutcomes_8_timeFrame,protocolSection_outcomesModule_secondaryOutcomes_0_measure,protocolSection_outcomesModule_secondaryOutcomes_0_description,protocolSection_outcomesModule_secondaryOutcomes_0_timeFrame,protocolSection_outcomesModule_secondaryOutcomes_1_measure,protocolSection_outcomesModule_secondaryOutcomes_1_description,protocolSection_outcomesModule_secondaryOutcomes_1_timeFrame,protocolSection_outcomesModule_secondaryOutcomes_2_measure,protocolSection_outcomesModule_secondaryOutcomes_2_description,protocolSection_outcomesModule_secondaryOutcomes_2_timeFrame,protocolSection_outcomesModule_secondaryOutcomes_3_measure,protocolSection_outcomesModule_secondaryOutcomes_3_description,protocolSection_outcomesModule_secondaryOutcomes_3_timeFrame,protocolSection_outcomesModule_secondaryOutcomes_4_measure,protocolSection_outcomesModule_secondaryOutcomes_4_description,protocolSection_outcomesModule_secondaryOutcomes_4_timeFrame,protocolSection_outcomesModule_secondaryOutcomes_5_measure,protocolSection_outcomesModule_secondaryOutcomes_5_description,protocolSection_outcomesModule_secondaryOutcomes_5_timeFrame,protocolSection_outcomesModule_secondaryOutcomes_6_measure,protocolSection_outcomesModule_secondaryOutcomes_6_description,protocolSection_outcomesModule_secondaryOutcomes_6_timeFrame,protocolSection_outcomesModule_secondaryOutcomes_7_measure,protocolSection_outcomesModule_secondaryOutcomes_7_description,protocolSection_outcomesModule_secondaryOutcomes_7_timeFrame,protocolSection_outcomesModule_secondaryOutcomes_8_measure,protocolSection_outcomesModule_secondaryOutcomes_8_timeFrame,protocolSection_outcomesModule_secondaryOutcomes_9_measure,protocolSection_outcomesModule_secondaryOutcomes_9_timeFrame,protocolSection_outcomesModule_secondaryOutcomes_10_measure,protocolSection_outcomesModule_secondaryOutcomes_10_description,protocolSection_outcomesModule_secondaryOutcomes_10_timeFrame,protocolSection_outcomesModule_secondaryOutcomes_11_measure,protocolSection_outcomesModule_secondaryOutcomes_11_timeFrame,protocolSection_outcomesModule_secondaryOutcomes_12_measure,protocolSection_outcomesModule_secondaryOutcomes_12_timeFrame,protocolSection_outcomesModule_secondaryOutcomes_8_description,protocolSection_outcomesModule_secondaryOutcomes_13_measure,protocolSection_outcomesModule_secondaryOutcomes_13_timeFrame,protocolSection_outcomesModule_secondaryOutcomes_9_description,protocolSection_outcomesModule_secondaryOutcomes_11_description,protocolSection_outcomesModule_secondaryOutcomes_12_description,protocolSection_outcomesModule_secondaryOutcomes_13_description,protocolSection_outcomesModule_secondaryOutcomes_14_measure,protocolSection_outcomesModule_secondaryOutcomes_14_description,protocolSection_outcomesModule_secondaryOutcomes_14_timeFrame,protocolSection_outcomesModule_secondaryOutcomes_15_measure,protocolSection_outcomesModule_secondaryOutcomes_15_description,protocolSection_outcomesModule_secondaryOutcomes_15_timeFrame,protocolSection_outcomesModule_secondaryOutcomes_16_measure,protocolSection_outcomesModule_secondaryOutcomes_16_description,protocolSection_outcomesModule_secondaryOutcomes_16_timeFrame,protocolSection_outcomesModule_secondaryOutcomes_17_measure,protocolSection_outcomesModule_secondaryOutcomes_17_description,protocolSection_outcomesModule_secondaryOutcomes_17_timeFrame,protocolSection_outcomesModule_secondaryOutcomes_18_measure,protocolSection_outcomesModule_secondaryOutcomes_18_description,protocolSection_outcomesModule_secondaryOutcomes_18_timeFrame,protocolSection_outcomesModule_secondaryOutcomes_19_measure,protocolSection_outcomesModule_secondaryOutcomes_19_description,protocolSection_outcomesModule_secondaryOutcomes_19_timeFrame,protocolSection_outcomesModule_secondaryOutcomes_20_measure,protocolSection_outcomesModule_secondaryOutcomes_20_description,protocolSection_outcomesModule_secondaryOutcomes_20_timeFrame,protocolSection_outcomesModule_secondaryOutcomes_21_measure,protocolSection_outcomesModule_secondaryOutcomes_21_description,protocolSection_outcomesModule_secondaryOutcomes_21_timeFrame,protocolSection_outcomesModule_secondaryOutcomes_22_measure,protocolSection_outcomesModule_secondaryOutcomes_22_description,protocolSection_outcomesModule_secondaryOutcomes_22_timeFrame,protocolSection_outcomesModule_secondaryOutcomes_23_measure,protocolSection_outcomesModule_secondaryOutcomes_23_description,protocolSection_outcomesModule_secondaryOutcomes_23_timeFrame,protocolSection_outcomesModule_secondaryOutcomes_24_measure,protocolSection_outcomesModule_secondaryOutcomes_24_description,protocolSection_outcomesModule_secondaryOutcomes_24_timeFrame,protocolSection_outcomesModule_secondaryOutcomes_25_measure,protocolSection_outcomesModule_secondaryOutcomes_25_description,protocolSection_outcomesModule_secondaryOutcomes_25_timeFrame,protocolSection_outcomesModule_secondaryOutcomes_26_measure,protocolSection_outcomesModule_secondaryOutcomes_26_description,protocolSection_outcomesModule_secondaryOutcomes_26_timeFrame,protocolSection_outcomesModule_secondaryOutcomes_27_measure,protocolSection_outcomesModule_secondaryOutcomes_27_description,protocolSection_outcomesModule_secondaryOutcomes_27_timeFrame,protocolSection_outcomesModule_secondaryOutcomes_28_measure,protocolSection_outcomesModule_secondaryOutcomes_28_description,protocolSection_outcomesModule_secondaryOutcomes_28_timeFrame,protocolSection_outcomesModule_secondaryOutcomes_29_measure,protocolSection_outcomesModule_secondaryOutcomes_29_description,protocolSection_outcomesModule_secondaryOutcomes_29_timeFrame,protocolSection_outcomesModule_secondaryOutcomes_30_measure,protocolSection_outcomesModule_secondaryOutcomes_30_description,protocolSection_outcomesModule_secondaryOutcomes_30_timeFrame,protocolSection_outcomesModule_secondaryOutcomes_31_measure,protocolSection_outcomesModule_secondaryOutcomes_31_description,protocolSection_outcomesModule_secondaryOutcomes_31_timeFrame,protocolSection_outcomesModule_secondaryOutcomes_32_measure,protocolSection_outcomesModule_secondaryOutcomes_32_description,protocolSection_outcomesModule_secondaryOutcomes_32_timeFrame,protocolSection_outcomesModule_secondaryOutcomes_33_measure,protocolSection_outcomesModule_secondaryOutcomes_33_description,protocolSection_outcomesModule_secondaryOutcomes_33_timeFrame,protocolSection_outcomesModule_secondaryOutcomes_34_measure,protocolSection_outcomesModule_secondaryOutcomes_34_description,protocolSection_outcomesModule_secondaryOutcomes_34_timeFrame,protocolSection_outcomesModule_secondaryOutcomes_35_measure,protocolSection_outcomesModule_secondaryOutcomes_35_description,protocolSection_outcomesModule_secondaryOutcomes_35_timeFrame,protocolSection_outcomesModule_secondaryOutcomes_36_measure,protocolSection_outcomesModule_secondaryOutcomes_36_description,protocolSection_outcomesModule_secondaryOutcomes_36_timeFrame,protocolSection_outcomesModule_secondaryOutcomes_37_measure,protocolSection_outcomesModule_secondaryOutcomes_37_description,protocolSection_outcomesModule_secondaryOutcomes_37_timeFrame,protocolSection_outcomesModule_secondaryOutcomes_38_measure,protocolSection_outcomesModule_secondaryOutcomes_38_description,protocolSection_outcomesModule_secondaryOutcomes_38_timeFrame,protocolSection_outcomesModule_secondaryOutcomes_39_measure,protocolSection_outcomesModule_secondaryOutcomes_39_description,protocolSection_outcomesModule_secondaryOutcomes_39_timeFrame,protocolSection_outcomesModule_secondaryOutcomes_40_measure,protocolSection_outcomesModule_secondaryOutcomes_40_description,protocolSection_outcomesModule_secondaryOutcomes_40_timeFrame,protocolSection_outcomesModule_secondaryOutcomes_41_measure,protocolSection_outcomesModule_secondaryOutcomes_41_description,protocolSection_outcomesModule_secondaryOutcomes_41_timeFrame,protocolSection_outcomesModule_secondaryOutcomes_42_measure,protocolSection_outcomesModule_secondaryOutcomes_42_description,protocolSection_outcomesModule_secondaryOutcomes_42_timeFrame,protocolSection_outcomesModule_secondaryOutcomes_43_measure,protocolSection_outcomesModule_secondaryOutcomes_43_description,protocolSection_outcomesModule_secondaryOutcomes_43_timeFrame,protocolSection_outcomesModule_secondaryOutcomes_44_measure,protocolSection_outcomesModule_secondaryOutcomes_44_description,protocolSection_outcomesModule_secondaryOutcomes_44_timeFrame,protocolSection_outcomesModule_secondaryOutcomes_45_measure,protocolSection_outcomesModule_secondaryOutcomes_45_description,protocolSection_outcomesModule_secondaryOutcomes_45_timeFrame,protocolSection_outcomesModule_secondaryOutcomes_46_measure,protocolSection_outcomesModule_secondaryOutcomes_46_description,protocolSection_outcomesModule_secondaryOutcomes_46_timeFrame,protocolSection_outcomesModule_secondaryOutcomes_47_measure,protocolSection_outcomesModule_secondaryOutcomes_47_description,protocolSection_outcomesModule_secondaryOutcomes_47_timeFrame,protocolSection_outcomesModule_secondaryOutcomes_48_measure,protocolSection_outcomesModule_secondaryOutcomes_48_description,protocolSection_outcomesModule_secondaryOutcomes_48_timeFrame,protocolSection_outcomesModule_secondaryOutcomes_49_measure,protocolSection_outcomesModule_secondaryOutcomes_49_description,protocolSection_outcomesModule_secondaryOutcomes_49_timeFrame,protocolSection_outcomesModule_secondaryOutcomes_50_measure,protocolSection_outcomesModule_secondaryOutcomes_50_description,protocolSection_outcomesModule_secondaryOutcomes_50_timeFrame,protocolSection_outcomesModule_otherOutcomes_0_measure,protocolSection_outcomesModule_otherOutcomes_0_description,protocolSection_outcomesModule_otherOutcomes_0_timeFrame,protocolSection_outcomesModule_otherOutcomes_1_measure,protocolSection_outcomesModule_otherOutcomes_1_description,protocolSection_outcomesModule_otherOutcomes_1_timeFrame,protocolSection_outcomesModule_otherOutcomes_2_measure,protocolSection_outcomesModule_otherOutcomes_2_description,protocolSection_outcomesModule_otherOutcomes_2_timeFrame,protocolSection_outcomesModule_otherOutcomes_3_measure,protocolSection_outcomesModule_otherOutcomes_3_description,protocolSection_outcomesModule_otherOutcomes_3_timeFrame,protocolSection_outcomesModule_otherOutcomes_4_measure,protocolSection_outcomesModule_otherOutcomes_4_description,protocolSection_outcomesModule_otherOutcomes_4_timeFrame,protocolSection_outcomesModule_otherOutcomes_5_measure,protocolSection_outcomesModule_otherOutcomes_5_description,protocolSection_outcomesModule_otherOutcomes_5_timeFrame,protocolSection_outcomesModule_otherOutcomes_6_measure,protocolSection_outcomesModule_otherOutcomes_6_description,protocolSection_outcomesModule_otherOutcomes_6_timeFrame,protocolSection_outcomesModule_otherOutcomes_7_measure,protocolSection_outcomesModule_otherOutcomes_7_description,protocolSection_outcomesModule_otherOutcomes_7_timeFrame,protocolSection_outcomesModule_otherOutcomes_8_measure,protocolSection_outcomesModule_otherOutcomes_8_description,protocolSection_outcomesModule_otherOutcomes_8_timeFrame,protocolSection_outcomesModule_otherOutcomes_9_measure,protocolSection_outcomesModule_otherOutcomes_9_description,protocolSection_outcomesModule_otherOutcomes_9_timeFrame,protocolSection_outcomesModule_otherOutcomes_10_measure,protocolSection_outcomesModule_otherOutcomes_10_description,protocolSection_outcomesModule_otherOutcomes_10_timeFrame,protocolSection_outcomesModule_otherOutcomes_11_measure,protocolSection_outcomesModule_otherOutcomes_11_description,protocolSection_outcomesModule_otherOutcomes_11_timeFrame,protocolSection_outcomesModule_otherOutcomes_12_measure,protocolSection_outcomesModule_otherOutcomes_12_description,protocolSection_outcomesModule_otherOutcomes_12_timeFrame
0,Adverse Drug Reaction,Proportion of subjects experiencing noxious pharmacologic activity/an Adverse Drug Reaction (ADR).,5 days after Tc 99m tilmanocept injection,,,,,,,,,,,,,,,,,,,,,,,,,Localization of Tc 99m tilmanocept,Determine the three dimensional tessellation localization of Tc 99m tilmanocept by planar and SPECT/CT imaging in subjects with NASH and asymptomatic controls.,5 days after Tc 99m tilmanocept injection,Localization of Tc 99m sulfur colloid,Determine the three dimensional tessellation localization of unfiltered Tc 99m sulfur colloid by planar and SPECT/CT imaging in subjects with NASH and asymptomatic controls.,5 days after Tc 99m tilmanocept injection,Localization Distribution Comparison,Comparison of liver localization distribution tessellation pattern intensities between Tc 99m tilmanocept and unfiltered Tc 99m sulfur colloid.,5 days after Tc 99m tilmanocept injection,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Tc 99m tilmanocept Localization Distribution of SPECT/CT vs Elastography,Concordance of intrahepatic localization tessellation discrimination of Tc 99m tilmanocept (intrahepatic disease heterogeneity) by SPECT/CT imaging and elastography.,5 days after Tc 99m tilmanocept injection,Tc 99m sulfur colloid Localization Distribution of SPECT/CT vs Elastography,Concordance of intrahepatic localization tessellation discrimination of Tc 99m sulfur colloid (intrahepatic disease heterogeneity) by SPECT/CT imaging and elastography.,5 days after Tc 99m tilmanocept injection,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1,Adverse Events,Incidences of treatment-emergent adverse events,Up to 28 days after last dose,Vital Signs,Incidences of clinically significant changes in vital signs,Up to 28 days after last dose,Laboratory tests,Incidences of clinically significant changes in laboratory tests,Up to 28 days after last dose,ECG,Incidences of clinically significant changes in ECGs,Up to 28 days after last dose,,,,,,,,,,,,,,,,Pharmacokinetic Profile of MET642,Cmax,16 weeks,Pharmacodynamic Profile of MET642,C4 concentrations,16 weeks,Pharmacological Activity of MET642,Measure of changes in liver fat using MRI-PDFF,20 weeks,Pharmacokinetic Profile of MET642,Tmax,16 weeks,Pharmacokinetic Profile of MET642,T1/2,16 weeks,Pharmacokinetic Profile of MET642,AUC0-inf,16 weeks,Pharmacodynamic Profile of MET642,FGF19 concentrations,16 weeks,Pharmacodynamic Profile of MET642,Bile Acids concentrations,16 weeks,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
2,Relative change from Baseline in liver-fat content assessed by MRI-PDFF compared to Baseline.,,Baseline Day 1 up to Week 24,,,,,,,,,,,,,,,,,,,,,,,,,Change from Baseline in aspartate aminotransferase (AST).,,Baseline Day 1 up to Week 24,Change from Baseline in alanine aminotransferase (ALT).,,Baseline Day 1 up to Week 24,Change from Baseline in gamma-glutamyl transferase (GGT).,,Baseline Day 1 up to Week 24,Change from baseline in enhanced liver fibrosis score (ELF).,"ELF numerical values are calculated from serum measurements of hyaluronic acid (HA), tissue inhibitor of metalloproteinases-1 (TIMP-1), and type III procollagen (PIIINP) using the formula: ELF score = 2.494 + 0.846 In \[HA\] + 0.735 In \[PIIINP\] + 0.391 In \[TIMP-1\], and range on a continuous scale. Liver fibrosis is unlikely with scores \<6.7 and increasingly likely with higher scores.",Baseline Day 1 up to Week 24,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
3,Change in liver-fat content assessed by MRI-PDFF after the last dose of study drug.,,Baseline Day 1 up to Month 12,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
4,Main: Proportion of participants with histological resolution of NASH without worsening of fibrosis,,24 Weeks,Main: Proportion of participants with ≥1 stage decrease in fibrosis stage with no worsening of NASH,,24 Weeks,,,,,,,,,,,,,,,,,,,,,,Main: Proportion of participants with at least a 2-point improvement in NAS and no worsening of fibrosis,,24 Weeks,Main: Proportion of participants with NASH resolution AND with ≥1 stage decrease in fibrosis stage,,24 Weeks,Main: Proportion of participants with at least a 2-point improvement in NAS and are MRI-PDFF responders AND ALT responders,,24 Weeks,Main: Absolute and percentage change from baseline in serum triglycerides,,"12 Weeks, 24 Weeks",Main: Absolute and percentage change from baseline in Low Density Lipoprotein (LDL) Cholesterol,,"12 Weeks, 24 Weeks",Main: Absolute change and percentage change from baseline in Alanine Transaminase (ALT),,"12 Weeks, 24 Weeks, 48 Weeks",Main: Absolute change and percentage change from baseline in N-terminal type III collagen propeptide (Pro-C3),,"12 Weeks, 24 Weeks, 48 Weeks",Main: Absolute change and percentage change from baseline in Magnetic Resonance Imaging - Hepatic Fat Fraction (MRI-PDFF),,"12 Weeks, 24 Weeks, 48 Weeks",Main: Percentage change from baseline in HbA1c,"12 Weeks, 24 Weeks",Main: Absolute and percentage change from baseline in Adiponectin,"12 Weeks, 24 Weeks",Main: Steady-state blood level of BIO89-100,Plasma trough concentration (ng/mL) of BIO89-100 taken at pre-dose samples,Blood samples for PK analysis collected at up to 8 study visits over the course of approximately 48 weeks,Main: Absolute and percentage change from baseline in Non High Density Lipoprotein (HDL) Cholesterol,"12 Weeks, 24 Weeks",Main: Absolute and percentage change from baseline in High Density Lipoprotein (HDL) Cholesterol,"12 Weeks, 24 Weeks",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
5,Relative Change From Baseline in Liver Fat Content Assessed by Magnetic Resonance Imaging-Proton Density Fat Fraction,"The change from baseline in liver fat content (LFC) by magnetic resonance imaging-proton density fat fraction (MRI-PDFF) for each miricorilant dose level (600 mg, 900 mg) versus placebo was assessed. MRI-PDFF was performed to determine the degree of LFC reduction. The relative change is defined for each participant as %: (\[Post-Baseline LFC-Baseline LFC\]/Baseline LFC) × 100. Due to observations related to safety, the study was terminated. If the participant had at least 6 weeks of treatment, the assessment was completed at the early termination visit. Due to the small sample size, no formal tests were performed to assess statistical differences between treatment groups.",Baseline and up to ~Day 95,,,,,,,,,,,,,,,,,,,,,,,,,Number of Participants Achieving a Relative Reduction From Baseline in LFC of ≥30% by MRI-PDFF,"The number of participants (defined as responders) with a ≥30% reduction in LFC from baseline by treatment group as assessed by MRI-PDFF. The number of participants with a reduction in LFC from baseline of \<30% were defined as non-responders. MRI-PDFF was performed at screening and up to 33 days after last dose of study drug. Due to observations related to safety, the study was terminated. If the participant had at least 6 weeks of treatment, the assessment was completed at the early termination visit. Due to the small sample size, no formal tests were performed to assess statistical differences between treatment groups.",Baseline and up to ~Day 95,Change From Baseline in Aspartate Aminotransferase,"The change in aspartate aminotransferase (AST) from baseline for each treatment group at the Week 6 visit is summarized. Due to the small sample size, no formal tests were performed to assess statistical differences between treatment groups.",Baseline and Week 6,Change From Baseline in Alanine Aminotransferase,"The change in serum alanine aminotransferase (ALT) from baseline for each treatment group at the Week 6 visit is summarized. Due to the small sample size, no formal tests were performed to assess statistical differences between treatment groups.",Baseline and Week 6,Change From Baseline in Gamma-glutamyl Transferase,"The change in gamma-glutamyl transferase (GGT) from baseline for each treatment group at the Week 6 visit is summarized. Due to the small sample size, no formal tests were performed to assess statistical differences between treatment groups.",Baseline and Week 6,Change From Baseline in Propeptide of Type III Collagen,"The change in serum propeptide of Type III collagen (pro-C3) from baseline at the Week 6 visit is summarized. Due to the small sample size, no formal tests were performed to assess statistical differences between treatment groups.",Baseline and Week 6,Change From Baseline in Enhanced Liver Fibrosis Score,"The change in enhanced liver fibrosis (ELF) from baseline for each treatment group at the Week 6 visit is summarized. The ELF score combines 3 serum biomarkers (hyaluronic acid, tissue inhibitor of metalloproteinases-1 \[TIMP-1\] and type III procollagen \[PIIINP\]) which have been shown to correlate with the degree of liver fibrosis assessed by liver biopsy. Each of these markers is measured by an immunoassay and an ELF score is generated \[ELF=2.278+0.851 ln(HA)+0.751 ln(PIIINP)+0.394 ln(TIMP-1)\], from which a level of fibrosis severity can be determined; higher ELF scores are associated with worsening liver fibrosis. Due to the small sample size, no formal tests were performed to assess statistical differences between treatment groups.",Baseline and Week 6,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Number of Participants With a Relative Reduction in Liver Fat Content ≥50% by Magnetic Resonance Imaging-Proton Density Fat Fraction (MRI-PDFF) for Miricorilant Versus Placebo,,Baseline and up to ~Day 95,Number of Participants With Complete Resolution in Liver Fat by MRI-PDFF for Miricorilant Versus Placebo,,Baseline and up to ~Day 95,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
6,Main: Absolute Change From Baseline in Hepatic Fat Fraction Assessed by MRI-PDFF at Week 12.,Main study. ANCOVA multiple imputation with treatment group and F1 fibrosis score (F1 vs F2-3) as factors and baseline hepatic fat fraction measured by MRI-PDFF as a covariate.,12 weeks,,,,,,,,,,,,,,,,,,,,,,,,,Main: Absolute Change From Baseline in Hepatic Fat Fraction Assessed by MRI-PDFF at Week 22-24.,Main study. Included subjects with ≥30% relative fat reduction on MRI-PDFF at Week 12 that were required to return between Weeks 22 - 24. ANCOVA model with treatment group and F1 fibrosis score (F1 vs F2-3) as factors and baseline hepatic fat fraction as a covariate were performed.,22-24 weeks,Main: Percent Change From Baseline in Hepatic Fat Fraction Measured by MRI-PDFF at Week 12.,Main study. ANCOVA multiple imputation with treatment group and F1 fibrosis score (F1 vs F2-3) as factors and baseline hepatic fat fraction measured by MRI-PDFF as a covariate.,12 weeks,Main: Percent Change From Baseline in Hepatic Fat Fraction Measured by MRI-PDFF at Week 22-24.,Main study. ANCOVA multiple imputation with treatment group and F1 fibrosis score (F1 vs F2-3) as factors and baseline hepatic fat fraction measured by MRI-PDFF as a covariate.,22-24 weeks,Main: Responder: Subjects Who Achieved a Clinically Meaningful Relative Reduction of at Least 30% in Liver Fat Content as Measured by MRI-PDFF at Week 12.,Main Study. The analyses included the treatment group and F1 fibrosis score (F1 vs F2-3) as factors and baseline hepatic fat fraction measured by MRI-PDFF as a covariate.,12 weeks,Main: Responder Based on NAFLD Activity Score System (NAS): Subjects Who Had a Decrease of ≥2 Points in NAS With at Least a 1-point Reduction in Either Lobular Inflammation or Hepatocellular Ballooning and With no Concurrent Worsening of Fibrosis Stage.,Main study: Responders were defined for subjects with ≥ 30% relative fat reduction on MRI-PDFF at Week 12 and required to return between Weeks 22 - 24. Fisher's exact test was used for the analysis using the Full Analysis Set with missing values imputed as non-responders and repeated on Liver Biopsy Evaluable Analysis Set without imputation.,22-24 weeks,"Main: Change From Baseline in ALT at Week 12, 16, and 20.","ANCOVA model with treatment group, baseline hepatic fat fraction (\<15% vs ≥15%), and F1 fibrosis score (F1 vs F2-3) as factors and baseline value as a covariate.","12, 16, and 20 weeks",Cohort C: Change From Baseline in Liver Stiffness as Evaluated by FibroScan at Week 16,Cohort C: ANCOVA model with treatment group as a factor and baseline liver stiffness as evaluated by FibroScan® as a covariate using the Full Analysis Set. Missing values at Week 16 were imputed using the last-observed-carried-forward (LOCF) method.,16 weeks,"Cohort C: Change From Baseline in Non-invasive Biomarkers Including Pro-C3 at Week 12, 16, and 20.",Cohort C. ANCOVA model with treatment group as a factor and baseline liver stiffness as evaluated by FibroScan® as a covariate using the Full Analysis Set. Missing values were imputed using the last-observed-carried-forward (LOCF) method.,"12, 16, and 20 weeks",Cohort C: Change From Baseline in Non-invasive Biomarkers Including Liver Fibrosis by ELF Test Score at Week 12 and 16.,12 and 16 weeks,,,,,,,,,,"Cohort C. The enhanced liver fibrosis (ELF) score describes the severity of liver fibrosis where a score of \<7.7 indicates no or mild fibrosis, a score of ≥7.7 to \<9.8 indicates moderate fibrosis, and a score of ≥9.8 indicates severe fibrosis. A change from baseline with a negative value indicates a decrease in severity of liver fibrosis.

An ANCOVA model with treatment group as a factor and baseline liver stiffness as evaluated by FibroScan® as a covariate using the Full Analysis Set was used. Missing values were imputed using the last-observed-carried-forward (LOCF) method.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
7,Change from baseline in liver fibrosis with no worsening steatohepatitis assessed by NASH CRN system,,24 Weeks,,,,,,,,,,,,,,,,,,,,,,,,,Resolution of steatohepatitis with no worsening of fibrosis assessed by the NASH CRN system,,"24 Weeks, 96 Weeks",Change from baseline in liver fibrosis with no worsening of steatohepatitis assessed by the NASH CRN system,,96 Weeks,Responder based on NASH CRN: patients who had a decrease of ≥ one point in fibrosis score,,"24 Weeks, 96 Weeks",Change from baseline in hepatic fat fraction,,"24 Weeks, 96 Weeks","Change from baseline of lipoproteins - Non-HDL-C, HDL-C, and LDL-C",,"24 Weeks, 48 Weeks, 96 Weeks",Change from baseline of markers of glycemic control - HbA1c,,"24 Weeks, 48 Weeks, 96 Weeks",Change from baseline of markers of glycemic control - C-Peptide,,"24 Weeks, 48 Weeks, 96 Weeks",Change from baseline of markers of glycemic control - Adiponectin,,"24 Weeks, 48 Weeks, 96 Weeks",Change from baseline of markers of glycemic control - HOMA-IR,"24 Weeks, 48 Weeks, 96 Weeks",Change from baseline of non-invasive fibrosis biomarkers - ELF,"24 Weeks, 48 Weeks, 96 Weeks",Change from baseline of non-invasive fibrosis biomarkers - Pro-C3,,"24 Weeks, 48 Weeks, 96 Weeks",Change from baseline of non-invasive fibrosis biomarkers - NIS-4,"24 Weeks, 48 Weeks, 96 Weeks",Change from baseline of non-invasive fibrosis biomarkers - liver stiffness assessed by transient elastography (FibroScan®),"24 Weeks, 48 Weeks, 96 Weeks",,Change from baseline of body weight,"24 Weeks, 48 Weeks, 96 Weeks",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
8,Change in liver stiffness on Magnetic Resonance Elastography (MRE),The investigators will assess for change in the MRE quantified liver stiffness in kilopascals (kPA),6 or 12 Months,,,,,,,,,,,,,,,,,,,,,,,,,Change in hepatic steatosis by Magnetic Resonance Proton Density Fat Fraction (PDFF),The investigators will assess for % change in fat fraction by MRI-PDFF,6 or 12 months,Change in visceral adipose tissue (VAT) volume by Magnetic Resonance Imaging (MRI),The investigators will assess for % change in VAT as quantified by MRI,6 or 12 months,Change HOMA-IR (Homeostatic model assessment (HOMA) for insulin resistance (IR)).,The investigators will assess change in continuous measures of HOMA-IR as insulin resistance is known to contribute to NASH progression.,6 or 12 Months,Change in the NAFLD activity score (NAS 0-8).,The investigators will assess for change in this histologic scoring system of NASH as a continuous measure among women willing to undergo end of treatment biopsy (not required).,6 or 12 Months,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
9,Determine Efficacy of ADI-PEG 20 vs Placebo in the treatment of fatty liver as assessed by change in hepatic fat fraction,Evaluate absolute change from baseline in hepatic fat fraction assessed by Magnetic Resonance Imaging - Proton Density Fat Fraction (MRI-PDFF) at Week 24,24 Weeks,,,,,,,,,,,,,,,,,,,,,,,,,Assess the Efficacy of ADI-PEG 20 vs Placebo reflected in the percent change from baseline in hepatic fat fraction at week 24,Evaluate percent change from baseline in hepatic fat fraction assessed by MRI-PDFF at Week 24,24 Weeks,Assess the safety of ADI-PEG 20 in subjects with NASH,Evaluate the change from baseline in ALT at Weeks 12 and 24.,24 Weeks,Assess the safety and tolerability of ADI-PEG 20 in subjects with NASH,Laboratory tests and clinical adverse events,24 Weeks,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
10,Non-Alcoholic Fatty Liver Disease (NAFLD) activity score (NAS),Proportion of subjects who achieve a ≥2-point improvement in the non-alcoholic fatty liver disease (NAFLD) activity score (NAS) of the Non-Alcoholic Steatohepatitis Clinical Research Network (NASH CRN),36 weeks,Adverse events (AEs),Incidence of AEs,36 weeks,,,,,,,,,,,,,,,,,,,,,,Alanine transaminase (ALT) mean,Mean percent change from Baseline in serum ALT level,36 weeks,Steady-state blood level of namodenoson,Plasma trough concentration (ng/mL) of namodenoson taken at pre-dose samples,36 weeks,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ALT absolute,Absolute change from Baseline in serum ALT,36 weeks,ALT threshold,Proportion of subjects who achieve ≥17-point reduction from Baseline in serum ALT,36 weeks,Weight,Change from Baseline in body weight,36 weeks,Adiponectin,Change from Baseline in serum adiponectin level,36 weeks,Released N-terminal pro-peptide of type III collagen neoepitope (Pro-C3),Change from Baseline in Pro-C3,36 weeks,Serum Enhanced Liver Fibrosis (ELF) Score,"Change from Baseline in ELF Score, which is a continuous scale starting at zero, with higher scores indicating more severe disease",36 weeks,FibroScan controlled attenuation parameter (CAP),Change from Baseline in CAP,36 weeks,FibroScan-AST (FAST) Score,"Change from Baseline in FAST Score, which is a decimal score from 0 to 1, with higher scores indicating more severe disease",36 weeks,Aspartate transaminase (AST),Change from Baseline in serum AST,36 weeks,Gamma-glutamyl transferase (GGT),Change from Baseline in serum GGT,36 weeks,Fibrosis-4 (Fib-4) Index,Change from Baseline in Fib-4 Index,36 weeks,NASH resolution,Proportion of subjects who achieve histologic NASH resolution as defined by a ballooning score of 0 and an inflammation score of 0-1 without worsening of fibrosis,36 weeks,NASH fibrosis improvement,Proportion of subjects who achieve histologic NASH improvement by at least 1 point without worsening of NASH,36 weeks
11,Relative Change From Baseline to Week 36 in the Percentage of Liver Fat Content (LFC) (Assessed by Magnetic Resonance Imaging - Proton Density Fat Fraction [MRI-PDFF]),"MRI-PDFF was performed using a standardized imaging protocol, and a central reader analyzed the results. The central reader for this study trained the local imaging centers and provided the imaging manual.

Relative change from baseline to Week 36 was calculated as follows: (LFC at Week 36 - LFC at baseline) / LFC at baseline x 100.

The primary analysis was performed for the Intent-to-treat Set (ITTS) using an analysis of covariance (ANCOVA) model adjusting for treatment, for stratification factors, and for the baseline LFC as a continuous covariate. LFC missing values at Week 36 were imputed using a multivariate imputation approach by fully conditional specification regression method assuming Missing At Random Mechanism.",Baseline and Week 36,Relative Change From Baseline to Week 36 in the Percentage of LFC (Assessed by MRI-PDFF) (Wilcoxon Test Sensitivity Analysis),"MRI-PDFF was performed using a standardized imaging protocol, and a central reader analyzed the results. The central reader for this study trained the local imaging centers and provided the imaging manual. The sensitivity analysis was performed for the Intent-to-treat Set (ITTS) using a non parametric pairwise Wilcoxon test stratified according to T2DM status and NASH CRN fibrosis scoring system. LFC missing values at Week 36 were imputed using a multivariate imputation approach by fully conditional specification regression method assuming Missing At Random Mechanism.",Baseline and Week 36,,,,,,,,,,,,,,,,,,,,,,Absolute Change From Baseline to Week 36 in the Percentage of LFC (Assessed by MRI-PDFF),"MRI-PDFF was performed using a standardized imaging protocol, and a central reader analyzed the results. The central reader for this study trained the local imaging centers and provided the imaging manual.

Absolute change from baseline to Week 36 was calculated as follows: LFC at Week 36 - LFC at baseline.

The analysis of the absolute change in LFC was performed for the Intent-to-treat Set (ITTS) using an ANCOVA model adjusting for treatment, for stratification factors, and for the baseline LFC as a continuous covariate. LFC missing values at Week 36 were imputed using a multivariate imputation approach by fully conditional specification regression method assuming Missing At Random Mechanism.",Baseline and Week 36,Percentage of Responders (Relative Reduction of at Least 30% in LFC) at Week 36,Responders were defined as patients who achieved a clinically meaningful relative reduction of at least 30% in LFC from baseline to Week 36 as assessed by MRI-PDFF,Baseline and Week 36,Change From Baseline to Week 36 in Alanine Amino Transferase (ALT),"Blood samples were collected, handled and stored according to the instructions described in the laboratory manual and all measurements were performed at a central laboratory.",Baseline to Week 36,Percentage of Responders (Normalization of ALT),"Normalization of ALT was analyzed in the subset of patients with baseline greater than the upper reference range. Patients were classed as responders if ALT normalized, i.e. decreased to \< upper reference range at a post baseline visit.",Baseline to Week 36,Change From Baseline to Week 36 in Aspartate Amino Transferase (AST),"Blood samples were collected, handled and stored according to the instructions described in the laboratory manual and all measurements were performed at a central laboratory.",Baseline to Week 36,Percentage of Responders (Normalization of AST),"Normalization of AST was analyzed in the subset of patients with baseline greater than the upper reference range. Patients were classed as responders if AST normalized, i.e. decreased to \< upper reference range at a post baseline visit.",Baseline to Week 36,Change From Baseline to Week 36 in Gamma Glutamyltransferase (GGT),"Blood samples were collected, handled and stored according to the instructions described in the laboratory manual and all measurements were performed at a central laboratory.",Baseline to Week 36,Change From Baseline to Week 36 in Alkaline Phosphatase (ALP),"Blood samples were collected, handled and stored according to the instructions described in the laboratory manual and all measurements were performed at a central laboratory.",Baseline to Week 36,Change From Baseline to Week 36 in Pro-C3,Baseline and Week 36,Change From Baseline to Week 36 in Enhanced Liver Fibrosis (ELF) Score,Baseline and Week 36,Change From Baseline to Week 36 in Fibrosis-4 (Fib-4) Score,"Fib-4 score is a non invasive method based on clinical determinations that indicates the level of fibrosis/ scarring of the liver. The set cutoffs for this scoring are: Fib-4 \< 1.45: absence of cirrhosis; Fib-4 between 1.45 - 3.25: inconclusive and Fib-4 \> 3.25: cirrhosis.

Fib-4 score was calculated as (Age \[years\] × AST \[U/L\]) / (platelet \[10\^9/L\] × √\[ALT \[U/L\]\]). Blood samples used for AST, ALT and platelet counts were collected, handled and stored according to the instructions described in the laboratory manual and all measurements were performed at a central laboratory.",Baseline and Week 36,Change From Baseline to Week 36 in NAFLD Fibrosis Score,Baseline and Week 36,Improvement of at Least 1 Point in NASH CRN Fibrosis Score From Baseline to Week 36,Baseline and Week 36,"Pro-C3 is the released N-terminal pro-peptide of type III collagen. It is a fibrosis marker.

Blood samples were collected, handled and stored according to the instructions described in the laboratory manual and all measurements were performed at a central laboratory.",Improvement in NAS of at Least 2 Points With no Worsening in NASH CRN Fibrosis Score From Baseline to Week 36,Baseline and Week 36,"ELF score is an extracellular matrix marker set consisting of tissue inhibitor of metalloproteinases 1 (TIMP-1), amino-terminal propeptide of type III procollagen (PIIINP) and hyaluronic acid (HA) showing good correlations with fibrosis stages in chronic liver disease.The set cutoffs for this scoring are: ELF \< 7.7: no to mild fibrosis; ELF between 7.7 - 9.8: moderate fibrosis; ELF between 9.8 - 11.3: severe fibrosis; and ELF \> or = 11.3: cirrhosis.

Blood samples used for TIMP-1, PIIINP and HA were collected, handled and stored according to the instructions described in the laboratory manual and all measurements were performed at a central laboratory.","The NFS is based on a combination of clinical and laboratory measurements (i.e. age, glycemia, BMI, platelet, albumin and AST/ALT ratio). The set cutoffs for this scoring are: \< -1.455 for exclusion of advance fibrosis, \> -1.455 to \< or = 0.675 for indetermined, and \> 0.675 for presence of advance fibrosis.

NFS was calculated as: 1.675 + 0.037 x age (years) + 0.094 x BMI (kg/m²) + 1.13 x Impaired Fasting Glucose or Diabetes (yes =1; no=0) + 0.99 x AST/ALT ratio - 0.013 x platelet (10\^9/L) - 0.66 x albumin (g/dL)",Improvement in fibrosis is defined as a decrease of at least one stage in NASH CRN fibrosis score.,"NAS is the NAFLD activity score, calculated as the sum of steatosis, lobular inflammation and ballooning scores. Improvement in NAS is defined as a decrease of at least 2 points. No worsening in NASH CRN fibrosis score means that the score remained stable or decreased.",NASH Resolution With no Worsening in NASH CRN Fibrosis Score at Week 36,"NASH resolution is defined as a NAS score of 0-1 for inflammation, 0 for ballooning, and any value for steatosis. No worsening in NASH CRN fibrosis score means that the score remained stable or decreased.",Baseline and Week 36,NASH Resolution With Improvement of at Least 1 Point in NASH CRN Fibrosis Score at Week 36,"NASH resolution is defined as a NAS score of 0-1 for inflammation, 0 for ballooning, and any value for steatosis. Improvement in fibrosis is defined as a decrease of at least one stage in NASH CRN fibrosis score.",Baseline and Week 36,Change From Baseline to Week 36 in Glycated Hemoglobin (HbA1c),"Blood samples were collected, handled and stored according to the instructions described in the laboratory manual and all measurements were performed at a central laboratory.",Baseline to Week 36,Change From Baseline to Week 36 in Fasting Plasma Glucose (FPG),"Blood samples were collected, handled and stored according to the instructions described in the laboratory manual and all measurements were performed at a central laboratory.",Baseline to Week 36,Change From Baseline to Week 36 in Serum Insulin,"Blood samples were collected, handled and stored according to the instructions described in the laboratory manual and all measurements were performed at a central laboratory.",Baseline to Week 36,Change From Baseline to Week 36 in Serum C-peptide,"Blood samples were collected, handled and stored according to the instructions described in the laboratory manual and all measurements were performed at a central laboratory.",Baseline to Week 36,Change From Baseline to Week 36 in Homeostasis Model Assessment of Insulin Resistance (HOMA-IR),"HOMA-IR was calculated as: Serum C-peptide (ng/mL) × FPG (mg/dL) / 405 Blood samples were collected, handled and stored according to the instructions described in the laboratory manual and all measurements were performed at a central laboratory.

HOMA-IR is an indicator of insulin resistance. The higher the value, the greater the insulin resistance. There is no minimum or maximum index score.",Baseline to Week 36,Change From Baseline to Week 36 in Quantitative Insulin Sensitivity Check Index (QUICKI),"The QUICKI was calculated as: 1 / (log (FPG \[mg/dL\]) + log (C-peptide \[ng/mL\])).

Blood samples were collected, handled and stored according to the instructions described in the laboratory manual and all measurements were performed at a central laboratory.

QUICKI is an indicator of insulin resistance. Lower numbers reflect greater insulin resistance. There is no minimum or maximum index score.",Baseline to Week 36,Change From Baseline to Week 36 in Adipo-IR,"The Adipo-IR was calculated as: Fasting serum Free Fatty Acids (mmol/L) x Fasting serum insulin (μIU/mL) Blood samples were collected, handled and stored according to the instructions described in the laboratory manual and all measurements were performed at a central laboratory.

The Adipo-IR is a marker of adipose tissue insulin resistance. Higher the value, the greater the insulin resistance. There is no minimum or maximum index score.",Baseline to Week 36,Change From Baseline to Week 36 in Adiponectin,"Blood samples were collected, handled and stored according to the instructions described in the laboratory manual and all measurements were performed at a central laboratory.",Baseline to Week 36,Change From Baseline to Week 36 in Weight,"Body weight was measured using a scale with appropriate resolution, placed on a stable, flat surface. Shoes, bulky layers of clothing, and jackets had to be removed so that only light clothing remained.",Baseline to Week 36,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
12,Main: Change from baseline in fibrosis with no worsening steatohepatitis assessed by NASH CRN system,Proportion of subjects who achieve ≥ 1 stage improvement in fibrosis (based on NASH CRN fibrosis score) and no worsening of steatohepatitis at Week 36.,Week 36,,,,,,,,,,,,,,,,,,,,,,,,,Main: Resolution of NASH with no worsening of fibrosis assessed by the NASH CRN system,Proportion of subjects who achieve NASH resolution (defined as a NAS of 0-1 for inflammation and 0 for ballooning) as determined by the NASH CRN criteria at Week 36 and Week 96,"Week 36, Week 96",Main: Change from baseline in fibrosis in subjects with no worsening of steatohepatitis assessed by the NASH CRN system,Proportion of subjects who achieve ≥ 1 stage improvement in fibrosis (based on NASH CRN fibrosis score) and no worsening of steatohepatitis at Week 96,Week 96,Main: Change from baseline in fibrosis in subjects with no worsening of steatohepatitis assessed by the NASH CRN system,Proportion of subjects who achieve ≥ 1 stage improvement in fibrosis (based on NASH CRN fibrosis score) at Week 36 and Week 96,"Week 36, Week 96",Main: Change from baseline in non-invasive markers of fibrosis,"Change from baseline in ELF score, Pro-C3 (ug/L),and liver stiffness assessed by liver elastography (kPa, CAP)","Week 36, Week 48, Week 72, Week 96",Main: Change from baseline in lipoproteins,"Change from baseline in Triglycerides (mg/dL), total cholesterol (mg/dL), HDL-C (mg/dL), non-HDL-C (mg/dL), and LDL-C (mg/dL)","Week 36, Week 48, Week 72, Week 96",Main: Change from baseline of markers in insulin sensitivity and glycemic control,"Change from baseline in HbA1c (%), C-peptide (ug/L), adiponectin (mg/L), insulin (mIU/L), and HOMA-IR","Week 36, Week 48, Week 72, Week 96",Main: Change from baseline in body weight,Change from baseline in body weight (kg),"Week 36, Week 48, Week 96",Main: To assess the immunogenicity of EFX,"Detect and measure ADA, including NAb, against EFX",Through Week 96,Main: To assess the safety and tolerability of EFX,Through Week 96,Cohort D: To assess the safety and tolerability of EFX compared to placebo when added to an existing GLP-1R agonist in subjects with type 2 diabetes and liver fibrosis due to NASH,Through Week 12,,,,,,,,"Safety and tolerability will be assessed through the reporting of AEs, clinical laboratory tests, ECGs, ultrasounds, vital sign assessments, and concomitant medication usage",,,"Safety and tolerability will be assessed through the reporting of AEs, clinical laboratory assessments, ECGs, ultrasounds, vital sign assessments, and concomitant medication usage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
13,safety and toxicity,"Number of participants with drug related Toxicity will follow standard Common Terminology Criteria for Adverse Events v.5,(CTCAE) criteria protocols. Toxicity is graded according to severity for symptoms obtained on the visit review of symptoms and according to blood tests collected at each scheduled visit",12-weeks per dose,Recommended Phase 2 dose,Of the 3 doses to be tested which one has the fewest Drug related toxicity,"for each dose, the number of AEs described over the 12 week period",,,,,,,,,,,,,,,,,,,,,,Liver transaminases,A decrease in the serum aminotransferases (ALT and AST) in IU by 10% or more,Comparison of baseline serum ALT and AST values to week 12 week values in IU,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,NASH score by Fibroscan,liver stiffness kPa score with a decrease by 4kPa and steatosis (CAPS) score in dB/m. a decline of 30 dB/m,baseline compared to week 12,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
14,Percent of patients with improvement of steatohepatitis and no worsening of liver fibrosis or improvement in liver fibrosis greater than or equal to one stage and no worsening of the steatohepatitis,Percent of patients with improvement of steatohepatitis on overall histopathological reading and no worsening of liver fibrosis on NASH-CRN Fibrosis Score or improvement in liver fibrosis greater than or equal to one stage and no worsening of the steatohepatitis,48 weeks,,,,,,,,,,,,,,,,,,,,,,,,,Percent of patients with resolution of steatohepatitis and no worsening of fibrosis or improvement of fibrosis by at least 1 stage and no worsening of steatohepatitis,,48 weeks,Percent of patients with steatohepatitis improvement and improvement of fibrosis by at least 1 stage,,48 weeks,Percent of patients with steatohepatitis resolution and improvement of fibrosis by at least 1 stage,,48 weeks,Percent of patients with steatohepatitis resolution and no worsening of fibrosis,,48 weeks,Percent of patients with steatohepatitis improvement and no worsening of fibrosis,,48 weeks,Change from baseline in liver fat content (LFC) as measured by MRI-PDFF,,48 weeks,"Change from baseline in liver chemistry（ALT,AST,GGT）",,48 weeks,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
15,Number of Participants With Adverse Events for TERN-101 Versus Placebo,,16 weeks,,,,,,,,,,,,,,,,,,,,,,,,,Percent Change From Baseline in ALT Outcome Measure,,12 weeks,Plasma Concentration of TERN-101 - AUC 0-24,Area under the curve,12 weeks (0-24 hours post dose),Plasma Concentration of TERN-101 - Cmax,Maximum observed concentration,12 Weeks (0-72 hours post dose),Plasma Concentration of TERN-101 - Tmax,Time to reach maximum measured plasma concentration,12 Weeks (0-72 hours post dose),Plasma Concentration of TERN-101 - t1/2,Determination of half-life,12 Weeks (0-72 hours post dose),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
16,Percentage Change From Baseline in Magnetic Resonance Imaging-proton Density Fat Fraction (MRI-PDFF),"Evaluate the effect of seladelpar on hepatic fat fraction, as assessed by magnetic resonance imaging-proton density fat fraction (MRI-PDFF) at Week 12 in the double-blind (DB) phase.

MRI-PDFF Relative (Percent) Change From Baseline to Week 12 - ANCOVA - mITT Population MRI-PDFF exam was used to quantify the hepatic proton density fat fraction noninvasively. The fat fraction is the proportion of mobile protons in liver tissue attributable to fat and thus, is a noninvasive magnetic resonance-based biomarker of liver triglyceride concentration.",Week 12,,,,,,,,,,,,,,,,,,,,,,,,,Percentage of Participants With Improvement of 2 Points or More in the Nonalcoholic Fatty Liver Disease Activity Score (NAS),"Histopathology nonalcoholic fatty liver disease activity score (NAS) change from baseline ≤-2 (Improvements of 2 points or more in NAS) - mITT Population Total NAS score represents the sum of scores for steatosis, lobular inflammation, and ballooning, and ranges from 0-8. Diagnosis of NASH (or, alternatively, fatty liver not diagnostic of NASH) should be made first, then NAS is used to grade activity. NAS scores of 0-2 occurred in cases largely considered not diagnostic of NASH, scores of 3-4 were evenly divided among those considered not diagnostic, borderline, or positive for NASH. Scores of 5-8 occurred in cases that were largely considered diagnostic of NASH",Week 52,Percent Change From Baseline in Alanine Aminotransferase (ALT) at Week 12 and Week 52,Alanine Aminotransferase (ALT) Relative (percent) change of from Baseline to Weeks 12 and Week 52 - mITT Population A decreased serum levels of alanine aminotransferase (ALT) is a marker of liver function improvement.,"Week 12, Week 52",Percent Change From Baseline in Aspartate Aminotransferase (AST) at Week 12 and Week 52,Relative (Percent) Change of Aspartate Aminotransferase (AST) From Baseline to Weeks 12 and Week 52 - mITT Population A decreased serum levels of Aspartate Aminotransferase (AST) is a marker of liver function improvement.,"Weeks 12, Week 52",Percent Change From Baseline in Gamma Glutamyl Transferase (GGT) at Week 12 and Week 52,Relative (Percent) Change of Gamma Glutamyl Transferase (GGT) From Baseline to Weeks 12 and Week 52 - mITT Population A decreased serum levels of Gamma Glutamyl Transferase (GGT) is a marker of liver function improvement.,"Weeks 12, Week 52",Number of Participants With Decrease in MRI-PDFF ≥ 30% From Baseline at Week 12 and Week 52,"Number of Participants with a relative decrease in MRI-PDFF ≥30% (ie, percent change ≥ 30%) at Weeks 12, and 52/ET (Early Termination) in the DB phase - mITT Population.

MRI-PDFF exam was used to quantify the hepatic proton density fat fraction noninvasively. The fat fraction is the proportion of mobile protons in liver tissue attributable to fat and thus, is a noninvasive magnetic resonance-based biomarker of liver triglyceride concentration.

MRI-PDFF response defined as ≥30% relative decline in MRI-PDFF is associated with ≥1 stage improvement in fibrosis and may be used as a surrogate marker of fibrosis regression in early phase clinical trials for NASH","Week 12, Week 52",Percentage Change From Baseline in Magnetic Resonance Imaging-proton Density Fat Fraction (MRI-PDFF) at Week 52,"Percentage Change from Baseline in MRI-PDFF to Weeks 52//ET - mITT Population MRI-PDFF exam was used to quantify the hepatic proton density fat fraction noninvasively. The fat fraction is the proportion of mobile protons in liver tissue attributable to fat and thus, is a noninvasive magnetic resonance-based biomarker of liver triglyceride concentration.",Week 52,Number of Liver Biopsy Responders With Reversal of NASH Reversal of NASH (Ballooning Score of 0 and Lobular Inflammation Score of 0 or 1) and no Worsening of Hepatic Fibrosis at Week 52,"Liver Biopsy Responders with reversal of NASH (ballooning score of 0 and lobular inflammation score of 0 or 1 and no worsening of hepatic fibrosis) at Week 52/ET.

The reversal of NASH was defined as the absence of hepatocellular ballooning (score of 0) and no or minimal inflammation (lobular inflammation score of 0 or 1).",Week 52,Percentage of Participants With Improvement by at Least 1 Stage in Fibrosis From Baseline at Week 12 and Week 52,"Proportion of subjects with improvement by at least 1 stage in fibrosis without worsening of NASH (ie, improvement by at least 1 fibrosis stage without worsening of NAS) at Week 52/ET - Cochran-Mantel-Haenszel - mITTb Population There five liver fibrosis stages (F0: no scarring (no fibrosis); F1: minimal scarring; F2: scarring has occurred and extends outside the liver area (significant fibrosis); F3: fibrosis spreading and forming bridges with other fibrotic liver areas (severe fibrosis); F4: cirrhosis or advanced scarring)",Week 52,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
17,Safety and tolerability of treatment,Number of participants Treatment-emergent adverse events (TEAEs),12 weeks,,,,,,,,,,,,,,,,,,,,,,,,,liver fat content,Change from baseline (CFB) in liver fat content (LFC) measured by magnetic resonance imaging-proton density fat fraction (MRI-PDFF) at Week 12,12 week,Percentage of subjects with ≥30% reduction in LFC from baseline,measured by MRI-PDFF at Week 4 and Week 12,4 week and 12 week,Change from baseline (CFB) in liver fat content (LFC) at 4 week,measured by MRI-PDFF at Week 4,4 week,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
18,Liver fibrosis,Reduction in degree of liver fibrosis,12 months,Liver fat,Reduction in amount of fat in the liver,12 months,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
19,Rate of disappearance of NASH without worsening of fibrosis grade,Diagnosis of NASH at the liver biopsy,at 48 weeks,,,,,,,,,,,,,,,,,,,,,,,,,Incidence of all Adverse Device Effects,"Safety will be characterized by the incidence of all Adverse Device Effects (ADEs), non-serious and serious, possibly related to or related to the procedure and/or device that are experienced by study participants.",at 48 weeks,Change in th SF-46 quality of life score,SF-36 quality of life score,at 48 weeks,Change in the NAS (NAFLD activity score) score,NAS is a histological score established on the liver biopsy. The NAS ranges form 0 to 8. 8 is associated with the highest severity.,at 48 weeks,"Change in liver histologic characteristics, such as steatosis, ballooning, lobular inflammation, and portal chronic inflammation scores.","Individual scores of the NAS score, the higher score (i.e. 8) means the worst condition.",at 48 weeks,Weight loss from randomization to the end of treatment,weight,at 48 weeks,Change in elastography measured by vibration-controlled transient elastography,Elastography is an indirect noninvasive measurement of liver fibrosis,at 48 weeks,Change in NAFLD fibrosis score,"NAFLD fibrosis score is a non invasive biomarker of liver fibrosis, a score superior to 0,675 means the worst condition",at 48 weeks,Change in Alanine Transaminase (ALT),"ALT is a liver enzyme, used for the biological liver test evaluation.",at 48 weeks,Change in Aspartate Transaminase (AST),at 48 weeks,Change in metabolic profile assessed by HOMA score,at 48 weeks,Change in Fasting glucose,fasting glucose is a marker of diabetes and insulin resistance,at 48 weeks,Change in Glycated haemoglobin,at 48 weeks,Change in HDL cholesterol,at 48 weeks,"AST is a liver enzyme, used for the biological liver test evaluation.",Change in serum triglycerides,at 48 weeks,HOMA is a score (scale) evaluating insulin resistance.,glycated haemoglobin is a surrogate marker for diabetes management and outcome.,HDL cholesterol is a biomarker for lipid metabolism and cardiovascular risk,serum triglycerides is a biomarker for lipid metabolism and cardiovascular risk,Change in LDL cholesterol,LDL cholesterol is a biomarker for lipid metabolism and cardiovascular risk,at 48 weeks,Change in total cholesterol.,total cholesterol is a biomarker for lipid metabolism and cardiovascular risk,at 48 weeks,Correlation between mediterranean diet score and NAS score change,"Mediterranean diet assessment score evaluate the compliance to the mediterranean diet, the highest score (i.e.5) means the highest adherence",at 48 weeks,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
20,Proportion of participants who achieve ≥ 1 stage improvement in liver fibrosis (NASH CRN Fibrosis Score),,At 12 weeks,,,,,,,,,,,,,,,,,,,,,,,,,Proportion of participants with ≥ 1 stage improvement in liver fibrosis with no increase of the NAS [NAFLD (Nonalcoholic fatty liver disease) Activity Score] by ≥ 1 point,,At 12 weeks,Proportion of participants with ≥ 2 stage improvement in liver fibrosis score (NASH CRN Fibrosis Score),,At 12 weeks,Proportion of participants with ≥ 1 stage improvement in modified Ishak liver fibrosis score,,At 12 weeks,Proportion of participants with ≥ 2 stage improvement in modified Ishak liver fibrosis score,,At 12 weeks,Change from baseline in collagen proportionate area (CPA),,At 12 weeks,Incidence of Adverse Events (AEs),,Up to week 36,Incidence of Serious Adverse Events (SAEs),,Up to week 36,Incidence of clinically significant changes in clinical laboratory values: Hematology tests,,Up to week 36,Incidence of clinically significant changes in clinical laboratory values: Clinical chemistry tests,Up to week 36,Incidence of clinically significant changes in clinical laboratory values: Urinalysis tests,Up to week 36,Incidence of clinically significant changes in vital signs: Body temperature,,Up to week 36,Incidence of clinically significant changes in vital signs: Respiratory rate,Up to week 36,Incidence of clinically significant changes in vital signs: Blood pressure,Up to week 36,,Incidence of clinically significant changes in vital signs: Heart rate,Up to week 36,,,,,Incidence of clinically significant changes in electrocardiogram (ECG) parameters: Mean heart rate,,Up to week 36,Incidence of clinically significant changes in electrocardiogram (ECG) parameters: PR interval,PR interval: The time from the onset of the P wave to the start of the QRS complex,Up to week 36,Incidence of clinically significant changes in electrocardiogram (ECG) parameters: QRS interval,"QRS interval: A combination of the Q wave, R wave and S wave, the ""QRS complex"" represents ventricular depolarization",Up to week 36,Incidence of clinically significant changes in electrocardiogram (ECG) parameters: QT interval,QT interval: Measured from the beginning of the QRS complex to the end of the T wave,Up to week 36,Incidence of clinically significant changes in electrocardiogram (ECG) parameters: QTcB interval,QTcB interval: Corrected QT interval using Bazett's formula (QTcB),Up to week 36,Incidence of clinically significant changes in electrocardiogram (ECG) parameters: QTcF interval,QTcF interval: Corrected QT interval using Fridericia's formula (QTcF),Up to week 36,Incidence of clinically significant changes in physical examination,,Up to week 36,"Change from baseline in bone mineral density (BMD), as measured by dual-energy x-ray absorptiometry (DXA) scan",,Up to week 36,Plasma concentrations of components of BMS-986263 for injection,,Day 1 to week 12,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
21,"Liver histology (Kleiner criteria, Hepatology 2005)",,6 months.,,,,,,,,,,,,,,,,,,,,,,,,,Liver fat content by MRS.,,6 months.,"Double-tracer OGTT (EGP, glucose clearance).",,6 months.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
22,Radiologic Diagnosis & Criteria of nonalcoholic steatohepatitis(NASH),"Development of non-invasive magnetic resonance imaging diagnostic model for NASH using linear regression analysis

1. Linear regression analysis using three magnetic resonance(MR) parameters 1) Fat signal fraction measured on MR spectroscopy (unit: %) 2) Liver stiffness measured on MR elastography (unit: kPa) 3) T1 relaxation time measured on T1 mapping (unit: msec) → Development of linear equation for NAFLD activity score (NAS) and Steatosis, Activity, Fibrosis (SAF) score
2. Fitting of observed values (NAS, SAF score) and predicted values (NAS, SAF score) → Obtaining R square (R2) (Unit: none)",up to 23 month,,,,,,,,,,,,,,,,,,,,,,,,,Fat imaging : Fat signal fraction measured on magnetic resonance(MR) spectroscopy,"\* Fat signal fraction measured on magnetic resonance(MR) spectroscopy

1. high speed T2-corrected multi-echo (HISTO) MR spectroscopic technique

   * multiple short echo time : correction of T2 bias
   * long repetition time: correction of T1 bias
2. 15 x 15 x 15-mm square-shaped region-of-interest(ROI) → Right hepatic lobe
3. 3 times measurement → mean value was used as a representative value
4. unit: percentage (%)
5. Receiver operating characteristic (ROC) curve analysis for steatosis grade (0-3) → Obtaining cut-off values of each steatosis grade and area under the curve (AUC)","During scanning, up to 15 seconds",Fibrosis imaging(1) : Liver stiffness measured on magnetic resonance elastography(MRE),"\* Magnetic resonance elastography(MRE)

1. 60 Hz acoustic wave
2. Four slices were obtained for each magnetic resonance elastography(MRE) examination
3. Stiffness maps (elastograms) for each magnetic resonance elastography(MRE) slices were automatically generated
4. free-hand region-of-interest (ROI) on the right hepatic lobe
5. 5 times measurement → mean value was used as a representative value
6. unit: kilopascal (kPa)
7. Receiver operating characteristic (ROC) curve analysis for fibrosis grade (0-4) → Obtaining cut-off values of each fibrosis grade and area under the curve (AUC)","During scanning, up to 20 seconds",Fibrosis imaging(2) : T1 relaxation time measured on T1 mapping,"\* T1 mapping

1. Shortened Modified Look Locker Inversion (shMOLLI) recovery sequence
2. Four slices were obtained for each T1 map
3. Oval-shaped region-of-interest (ROI) in the right hepatic lobe
4. 5 times measurement → mean value was used as a representative value
5. unit: millisecond (msec)
6. Receiver operating characteristic (ROC) curve analysis for ballooning (0-2), lobular inflammation (0-3), fibrosis grade (0-4) → Obtaining cut-off values of each grade and area under the curve (AUC)","During scanning, up to 20 seconds",Histologic interpretation(1) : Nonalcoholic fatty liver disease activity score (NAS),"1. the sum of each histological component semiquantitatively evaluated as follows: steatosis (0-3), ballooning (0-2), and lobular inflammation (0-3)
2. NAS 0-2: not considered steatohepatitis
3. NAS 3-4: possible steatohepatitis 4/ NAS ≥5: definite steatohepatitis",Up to a week,"Histologic interpretation(1) : Steatosis, Activity, Fibrosis (SAF) score","1. steatosis (0-3), ballooning degeneration (0-2), lobular inflammation (0-2), and fibrosis (0-4).
2. Nonalcoholic steatohepatitis(NASH): when steatosis is present and when both features of activity (ballooning and lobular inflammation) display at least grade 1
3. Unit: None",Up to a week,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
23,PK Profile of liquid formulation of BIO89-100,Determine maximum observed serum drug concentration (Cmax),22 days,PK Profile of liquid formulation of BIO89-100,Area under the serum drug concentration-by-time curve from time 0 to the time of the last quantifiable drug concentration (AUC0-t),22 days,,,,,,,,,,,,,,,,,,,,,,Evaluate the safety and tolerability of the BIO89-100 liquid formulation,"Frequency and severity of adverse events (AEs) and serious adverse events (SAEs)

Number of subjects who discontinued due to AEs and due to related AEs",22 days,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
24,Incidence of Adverse Event,Safety and Tolerability,up to Day 28,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
25,explore the anti-oxidant activity of Heptex,assessed by the change in serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels in patients with apparent risk factors of NASH.,36 weeks,,,,,,,,,,,,,,,,,,,,,,,,,explore the hepatoprotective effect of Heptex,"assessed by the change in Fibrosis score (F0 to F1: 2 to 7 kPa, F2: 7.5 to 10 kPa, F3: 10 to 14 kPa, F4: 14 kPa or higher) and by the occurrence of hepatic complications.",36 weeks,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,To explore the lipid-lowering effect of Heptex,To explore the lipid-lowering effect of Heptex as assessed by the change in lipid profile.,36 weeks,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
26,Change in NASH as measured by improvement in NAS score Improvement in NAS score (≥ 2 points) with no worsening in fibrosis stage (≥1 point) OR improvement in fibrosis with no worsening of NASH (change in the NAS score of ≤ 0 points).,One overall score of NASH improvement will be derived from improvement in NAS score OR no worsening in fibrosis.,"Baseline, 96 weeks",,,,,,,,,,,,,,,,,,,,,,,,,NASH resolution as measured by (diagnosis by pathologist) (from definite- to not- NASH).....,Histological change from NASH to No NASH,"Baseline, 96 weeks",Change in fibrosis stage as measured by change in stage,Ordinal variable,"Baseline, 96 weeks",Change in each component of NASH histologic features as measured by presence or ab presence or absence of features or their severity.,Existing features may improve in severity or disappear as an indication of improvement of NASH.,"Baseline, 96 weeks",Change in serum aminotransferase (ALT) and aspartate aminotransferase (AST) levels as measured by plasma concentrations,,"Baseline, 96 weeks","Change in makers of hepatic fibrosis markers as measured by (FIB-4,51 liver stiffness by Fibroscan®)",,"Baseline, 96 weeks",Change in capture attention parameter (CAP) score (with Fibroscan®),,"Baseline, 96 weeks",Serum creatine phosphokinase (CPK) as measured by serum concentration,,"Baseline, 96 weeks",Change in serum lipids as measured by serum concentration,,"Baseline, 96 weeks",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
27,"Safety of duodenal mucosal resurfacing characterized by the incidence of all Adverse Device Effects (ADEs), and subsequent adverse events [ Time Frame: 12 months ] in patients with NASH.","Safety will be characterized by the incidence of all Adverse Device Effects (ADEs), non-serious and serious, possibly related to or related to the procedure and/or device that are experienced by study participants.

Safety evaluations will also be performed to ensure no subsequent adverse events have occurred and to ensure any adverse events during the trial that are considered on-going are stable or have resolved. Safety will be assessed at 1 and 6 months following the intervention.",12 months,,,,,,,,,,,,,,,,,,,,,,,,,Change in Magnetic Resonance Fat Fraction (MRFF) from baseline in the following 6 months in DMR subjects.,Magnetic Resonance Fat fraction,baseline and 6 months post-procedure,Change in NAS score from baseline in the following 12 months in DMR subjects.,"Centrally scored histological improvement in NAFLD from baseline to the end of 12 months post-procedure, where improvement is defined as:

* No worsening in fibrosis; and
* A decrease in NAFLD Activity Score (NAS) of at least 2 points",baseline and 12 months post-procedure,Change in Fibrosis-4 Index for Liver Fibrosis (FIB-4) from baseline in the following at 6 months in DMR subjects,Absolute change in Fibrosis-4 Index for Liver Fibrosis (FIB-4) is a fibrosis marker. A score \<1.45 has a negative predictive value of over 90% for advanced liver fibrosis. A score of \>3.25 has a positive predictive value of 65% for advanced fibrosis with a specificity of 97%.,baseline and 6 months post-procedure,Change in Fibrosis-4 Index for Liver Fibrosis (FIB-4) from baseline in the following at 12 months in DMR subjects,Absolute change in Fibrosis-4 Index for Liver Fibrosis (FIB-4) is a fibrosis marker. A score \<1.45 has a negative predictive value of over 90% for advanced liver fibrosis. A score of \>3.25 has a positive predictive value of 65% for advanced fibrosis with a specificity of 97%.,baseline and 12 months post-procedure,Change in Transient Elastography using Firboscan from baseline in the following at 6 months in DMR subjects,Transient Elastography,baseline and 6 months post-procedure,Change in Transient Elastography using Firboscan from baseline in the following at 12 months in DMR subjects,Transient Elastography,baseline and 12 months post-procedure,Change in Magnetic Resonance Fat Fraction (MRFF) from baseline in the following 12 months in DMR subjects.,Magnetic Resonance Fat fraction,baseline and 12 months post procedure,Change in transaminases levels from baseline in the following 6 months in DMR subjects,Transaminases levels,baseline and 6 months post-procedure,Change in transaminases levels from baseline in the following 12 months in DMR subjects,baseline and 12 months post-procedure,Change in Insulin resistance measured by oral glucose tolerance test (OGTT) from baseline in the following 6 months in DMR subjects,baseline and 6 months post-procedure,Change in Insulin resistance measured by oral glucose tolerance test (OGTT) from baseline in the following 12 months in DMR subjects,Insulin resistance as abnormal HOMA IR,baseline and 12 months post procedure,Change in stage of fibrosis from baseline in the following 12 months in DMR subjects,baseline and 12 months post-procedure,,,Transaminases levels,,,Insulin resistance as abnormal HOMA IR,Liver histology,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
28,Diagnostic performance of cT1,"To evaluate, in patients with suspected Nash referred for Liver biopsy, the diagnostic performance of cT1 at discriminating those patients with NAS≥4 \& F≥2 from those patients without. In order to evaluate the diagnostic performance area under the receiver operative curve (AUROC) will be analysised.",12 months,,,,,,,,,,,,,,,,,,,,,,,,,Diagnostics performance of PDFF,"To evaluate, inpatients with suspected NASH referred for liver biopsy, the diagnostic performance of PDFF at discriminating those with NAS≥4 from those without, and those with Brunt Steatosis≥2 from those without. The diagnostic performance will be determined using area under the receiver operative curve (AUROC) analysis.",12 months,Correlation between cT1 and hisopathological features,To assess the correlation between cT1 and histopathological features of NASH and PDFF and histopathological features of NASH. The correlations will be explored using Spearman's Rho,12 months,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
29,Week 52 Dual Primary Objectives: To determine the effect of 80 or 100 mg MGL-3196 vs matching placebo on liver biopsy (NASH CRN score) at Week 52 compared with Baseline,"1. Proportion with resolution of NASH (ballooning 0, inflammation 0,1) associated with at least 2-point reduction in NAFLD Activity Score (NAS) without worsening of fibrosis stage OR
2. Proportion with at least a 1-point improvement in fibrosis stage with no worsening of NAS",52 weeks,"Month 54 Primary Objective: Time to experiencing an adjudicated Composite Clinical Outcome event (Final Primary Endpoint, at 54 months)","The Composite Clinical Outcome is composed of all-cause mortality, liver transplant, and significant hepatic events (including hepatic decompensation events \[ascites, encephalopathy, or gastroesophageal variceal hemorrhage\], histological progression to cirrhosis, and a confirmed increase of MELD score from \<12 to ≥15).",up to 54 months,,,,,,,,,,,,,,,,,,,,,,"Week 52 Key Secondary Objective: To determine the effect of once-daily, oral administration of MGL-3196 80 or 100 mg versus matching placebo on the percent change from Baseline at 24 weeks in directly measured low-density lipoprotein cholesterol (LDL-C)",Assess the effect of MGL-3196 80 mg or 100 mg compared to placebo on LDL-C measured by percent change from Baseline at 24 weeks.,24 weeks,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
30,"changes in degree of steatosis, necroinflammatory activity and fibrosis in liver biopsy.",,1 year,,,,,,,,,,,,,,,,,,,,,,,,,Secondary end-points will be changes in liver test results and health related quality of life.,,1 year,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
31,Safety-related endpoints - Treatment emergent adverse events (TEAEs),The safety and tolerability will be assessed by monitoring treatment emergent adverse events (TEAEs),14-week treatment period,,,,,,,,,,,,,,,,,,,,,,,,,Serum biomarkers for pharmacodynamic parameters - Enhanced liver function (ELF™) Blood Test,Change in serum biomarkers for Enhanced liver function (ELF™) Blood Test,Change from baseline to week 16,Serum biomarkers for pharmacodynamic parameters - Pro-C3,Change in serum biomarkers for Pro-C3,Change from baseline to week 16,Serum biomarkers for pharmacodynamic parameters - PRO-C4,Change in serum biomarkers for PRO-C4,Change from baseline to week 16,Serum biomarkers for pharmacodynamic parameters - C3M,Change in serum biomarkers for C3M,Change from baseline to week 16,"Serum biomarkers for pharmacodynamic parameters - Cytokeratin-18 (cCK-18) (full length and fragments; M65, M30)","Change in serum biomarkers for Cytokeratin-18 (cCK-18) (full length and fragments; M65, M30)",Change from baseline to week 16,Serum inflammatory markers - Fibrinogen,Change over time in serum inflammatory markers - Fibrinogen,From baseline over time,Serum inflammatory markers - C-reactive protein (CRP),Change over time in serum inflammatory markers - C-reactive protein (CRP),From baseline over time,Change in liver enzymes,"Absolute and percentage changes from Baseline over time through to week 16 as well as the percentage of normalization of ALT, AST, ALP, GGT, total bilirubin (TB) triglycerides and lipid profile (total cholesterol, HDL C, LDL C)",From baseline over time,Immune cell sub populations evaluation,16 weeks,Change in Liver Stiffness,Change from Baseline to week 16,Change in Liver Fat Content,Change from Baseline to week 8 and 16 in LFC (Liver fat content) assessed by MRI-PDFF,Change from Baseline to week 16,Change in liver fibrosis - Fibrosis-4 (FIB-4) score,16 weeks,Change in liver fibrosis - AST/ALT ratio,16 weeks,Whole Blood sampling for immune cell sub populations evaluation,Change in liver fibrosis -APRI (AST to platelet ratio index),16 weeks,Change from Baseline to week 8 and 16 in liver stiffness using Transient Elastography,Change from baseline to week 16 in: fibrosis-4 (FIB-4) score,Change from baseline to week 16 in: AST/ALT ratio,Change from baseline to week 16 in: APRI (AST to platelet ratio index),Change in liver fibrosis -the Nonalcoholic fatty liver disease (NAFLD) Fibrosis Score,Change from baseline to week 16 in: the Nonalcoholic fatty liver disease (NAFLD) Fibrosis Score,16 weeks,Pharmacokinetics (PK) profile - Cmax,Elucidate CM-101 Serum PK profile - Observed maximum plasma concentration,14 weeks,Pharmacokinetics (PK) profile - Tmax,Elucidate CM-101 Serum PK profile - Time to reach the observed maximum plasma concentration (Cmax),14 weeks,Pharmacokinetics (PK) profile - AUC∞,"Elucidate CM-101 Serum PK profile - Area under the plasma concentration-time curve extrapolated to infinity, calculated as: AUC∞ = AUClast + Clast/λz, where AUClast is the last measurable concentration.",14 weeks,Pharmacokinetics (PK) profile - t½,"Elucidate CM-101 Serum PK profile - Terminal elimination half-life, defined as 0.693/λz",14 weeks,Anti-Drug Antibodies,Evaluation of the development of anti-drug antibodies (ADA) following 14 weeks repeated administration,14 weeks,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
32,"NASH reduction: the main expected benefit is resolution of NASH, and no worsening of fibrosis","Evolution of the SAF score and CAP elastometry, a composite histological score taking into account the improvement of Steatosis, histological activity and liver fibrosis",At 6 months,,,,,,,,,,,,,,,,,,,,,,,,,"Initial correlation of NASH parameters (FIB4, NAFLD and liver stiffness) and symbiosis parameters (stool analysis by Shallow Shotgun, biological data specific to symbiosis).",,At the screening,Follow up of transaminase levels,,At 6 months,Reduction of hepatic steatosis measured by CAP elastometry and Hepatic MRI,,At 6 months,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Follow up of Biological Scores (FIB4, NAFLD) throughout the study",,At 6 months,"Follow up of symbiosis throughout the study, analysis of stool of the microbiota and measurement of the biological parameters of the symbiosis; correlation with the evolution of NASH.",,At 6 months,"Follow up of metabolic syndrome settings throughout the study : weight, waistline, blood pressure, Glycemia, Insulinemia, Gycated Hemoglonin level, Ferritinaemia, Triglyceridemia, HDL Cholesterol, LDL Cholesterol, Apolipoproteine A1, Homa score.",,At 6 months,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
33,MRI-PDFF Change From Baseline to Week 14,Change in hepatic fat fraction from baseline assessed by magnetic resonance imaging-derived proton density fat fraction (MRI-PDFF) at week 14,"Change from baseline (day one, first day of treatment) to EOT (day 92, 13 weeks of treatment)",,,,,,,,,,,,,,,,,,,,,,,,,MRI-cT1 Change From Baseline to Week 14,MRI corrected T1 (cT1) is emerging as a promising quantitative surrogate metric for assessing a composite of liver inflammation and fibrosis.,Measured at baseline (day 1) and at EOT (day 92),Alkaline Phosphatase,Change from Baseline to Week 14 in Alkaline Phosphatase,Measured at baseline (day 1) and at EOT (day 92),Alanine Aminotraferase (ALT),Change from Baseline to Week 14 in Alanine Aminotraferase (ALT),Measured at baseline (day 1) and at day 92,Aspartate Aminotransferase (AST),Change from Baseline to Week 14 in Aspartate Aminotransferase (AST),Measured at baseline (day 1) and at EOT (day 92),GGT S,"Change from Baseline to Week 14 in Gamma Glutamyl transferase, GGT S",Measured at baseline (day 1) and at EOT (day 92),Neutrophils/Leukocytes,Change in Neutrophils/Leukocytes ratio from Baseline to Week 14,"Measured at baseline (day 1, start of treatment) and at EOT (day 92)",CCL2,Change from Baseline to Week 14 in Monocyte Chemotactic Protein 1 (CCL2),Measured at baseline (day 1) and at EOT (day 92),CCL3,"Change from Baseline (day 1, start of treatment) to Week 14 (EOT) in Macrophage Inflammatory Protein 1 Alpha","Measured at baseline (day 1, start of treatment) and at EOT (day 92)",CCL5 (Rantes),Measured at baseline (day 1) and at EOT (day 92),Fibro Test Score,"Measured at baseline (day 1, start of treatment) and at EOT (day 92)",CCL11( Eotaxin-1),Change from Baseline to Week 14 in Eosinophils Chemotactic Protein,"Measured at baseline (day 1, start of treatment) and at EOT (day 92)",CCL18,Measured at baseline (day 1) and at EOT (day 92),VCAM,Measured at baseline (day 1) and at EOT (day 92),Change from Baseline to Week 14 in CCL-5 (Rantes),Interleukin-1 Beta,Measured at baseline (day 1) and at EOT (day 92),"Change from baseline (day 1, start of treatment) to Week 14 (EOT) in Fibro Test Score measured on a scale of 0 to 1, where 0 to 0.27 is no fibrosis, 0.27 to 0.48 is minimal fibrosis, 0.48 to 0.58 is moderate fibrosis, 0.58 to 0.74 is advanced fibrosis and 0.74 to 1.00 is severe fibrosis (Cirrhosis). Minimum score is zero, maximum score (worst outcome) is 1.",Change from Baseline to week 14 in CCL18 (Pulmonary \& Activation-Reg Chemokine),Change from Baseline to Week 14 in Vascular Cell Adhesion Molecule 1,Change from Baseline to Week 14 in Interleukin-1 Beta,IL-1RA,Change from Baseline to Week 14 in Interleukin 1 Receptor Antagonist,Measured at baseline (day 1) and at EOT (day 92),IL-6,Change from Baseline to Week 14 in Interleukin 6,Measured at baseline (day 1) and at EOT (day 92),IL-8,Change from Baseline to Week 14 in Interleukin 8,Measured at baseline (day 1) and at EOT (day 92),TNF Receptor 2,"Change from baseline (day 1, start of treatment) to Week 14 (EOT) in Tumor Necrosis Factor Receptor 2","Measured at baseline (day 1, start of treatment) and at EOT (day 92)",TIMP-1,"Change from Baseline (day 1, start of treatment) to Week 14 (EOT) in Tissue Inhibitor of Metalloproteinases 1 (ng/mL)",Measured at baseline (day 1) and at EOT (day 92),En Rage,"Change from baseline (start of treatment, day 1) to Week 14 (EOT) in En Rage (Receptor Advanced Glycation End-Products)",Measured at baseline (day 1) and at EOT (day 92),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
34,Part A and Part B: Number of participants with treatment-emergent adverse events (TEAE) and treatment-emergent serious adverse events (TESAE),The effects of BOS-580 on safety and tolerability will be assessed.,Until End of study/Early Termination (Day 197),Part A and Part B: Changes from Baseline to Week 12 (Day 85) in systolic and diastolic blood pressure (BP),The effects of BOS-580 on safety and tolerability will be assessed.,"Baseline, Week 12 (Day 85)",Part A and Part B: Changes from Baseline to Week 12 (Day 85) in heart rate,The effects of BOS-580 on safety and tolerability will be assessed.,"Baseline, Week 12 (Day 85)",Part A and Part B: Number of participants with Grade 3 and Grade 4 laboratory abnormalities at Week 12 (Day 85),The effects of BOS-580 on safety and tolerability will be assessed.,Week 12 (Day 85),Part B only: Changes from Baseline to Week 24 (Day 169) and Week 28 (Day 197) in systolic and diastolic BP,The effects of BOS-580 on safety and tolerability will be assessed.,"Baseline, Week 24 (Day 169), Week 28 (Day 197)",Part B only: Changes from Baseline to Week 24 (Day 169) and Week 28 (Day 197) in heart rate,The effects of BOS-580 on safety and tolerability will be assessed.,"Baseline, Week 24 (Day 169), Week 28 (Day 197)",Part B only: Number of participants with Grade 3 and Grade 4 laboratory abnormalities at Week 24 (Day 169) and Week 28 (Day 197),The effects of BOS-580 on safety and tolerability will be assessed.,Week 24 (Day 169) and Week 28 (Day 197),,,,,,,Part A only: BOS-580 serum concentration on Day 8 of the first dose,The pharmacokinetics (PK) of BOS-580 will be assessed.,Day 8,Part A only: BOS-580 serum concentration at the end of the dosing interval (Ctrough),The pharmacokinetics (PK) of BOS-580 will be assessed.,"Pre-dose at Days 15, 29, 43, 57, 71, 85 and 113 (End of study/Early termination) for bi-weekly schedule; pre-dose on Days 29, 57, 85 and 113 (End of study/Early termination) for the monthly schedule",Part B only: BOS-580 serum concentration on Day 7,The PK of BOS-580 will be assessed.,Day 7,Part B only: BOS-580 serum concentration at the end of the dosing interval (Ctrough),The PK of BOS-580 will be assessed.,"Pre-dose at Days 29, 57, 85, 113, 141, 169 and at Day 196 (End of study/Early Termination)",Part B Only: Area under the serum concentration-time curve (AUC) for BOS-580 for one dosing interval at steady state,The PK of BOS-580 will be assessed.,"At Days 121, 127, 134 and pre-dose at Day 141",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
35,NASH resolution,NASH resolution evaluated by liver biopsy,12 months,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
36,Percentage of Participants with Absence of NASH with no Worsening of Fibrosis on Liver Histology,Percentage of Participants with Absence of NASH with no Worsening of Fibrosis on Liver Histology,Week 52,,,,,,,,,,,,,,,,,,,,,,,,,Percentage of Participants with ≥1 Point Decrease in Fibrosis Stage with No Worsening of NASH on Liver Histology,Percentage of Participants with ≥1 Point Decrease in Fibrosis Stage with No Worsening of NASH on Liver Histology,Week 52,Percentage of Participants with ≥1 Point Increase in Fibrosis Stage on Liver Histology,Percentage of Participants with ≥1 Point Increase in Fibrosis Stage on Liver Histology,Week 52,"Percentage of Participants that Achieve a ≥2 Point Decrease in NAFLD (non-alcoholic fatty liver disease) Activity Score (NAS) on Liver Histology, with ≥1 Point Reduction in at Least 2 NAS Components","Percentage of Participants that Achieve a ≥2 Point Decrease in NAS on Liver Histology, with ≥1 Point Reduction in at Least 2 NAS Components",Week 52,Mean Absolute Change from Baseline in Liver Fat Content by Magnetic Resonance Imaging - Proton Density Fat Fraction (MRI-PDFF),Mean Absolute Change from Baseline in Liver Fat Content by MRI-PDFF,"Baseline, Week 52",Mean Change from Baseline in Body Weight,Mean Change from Baseline in Body Weight,"Baseline, Week 52",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
37,Percent of ASC41 subjects compared to placebo with histological reduction in NAS ≥2 points that results from reduction of inflammation or ballooning and no worsening fibrosis assessed by histopathological reading of liver biopsy at Week 52,,Baseline to Week 52,,,,,,,,,,,,,,,,,,,,,,,,,Safety and tolerability of ASC41 evaluated by incidence of treatment emergent adverse events (TEAEs) in ASC41 treated subjects compared to placebo,,Baseline to Week 52,Change in hepatic fat fraction based on MRI-PDFF measurements in ASC41 treated subjects compared to placebo.,,Baseline to Week 12 and Week 52,Resolution of NASH on overall histopathological reading of liver biopsy specimen taken at Week 52 compared to baseline in ASC41 treated subjects compared to placebo treated subjects,,Baseline to Week 52,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
38,Resolution of NASH and improvement of fibrosis,"Part A: DBPC: Resolution of NASH and improvement of fibrosis at Week 72, defined by NASH CRN scores for ballooning of 0 and inflammation of 0 to 1, and fibrosis score ≥1 stage decrease compared to Baseline",Part A: Date of randomisation until the date of biopsy at Week 72,Safety Analyses,"Part B: ATE:

* Using the DBPC on-treatment period, comparing the 2 active arms versus placebo
* Using the DBPC +ATE on treatment periods, assessing the 2 active arms. For adverse events, adjudicated liver events, and DILI and MACE events, in addition to the raw cumulative incidence proportions, the exposure-adjusted incidence rates will be provided based on the time patients are at risk.",48 weeks after completion of DBPC period,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
39,"Number of participants with resolution of NASH, assessed by centrally scored liver histology, and no worsening of fibrosis AND/OR improvement of fibrosis, and no worsening of NAS",,72 weeks,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
40,Overall Safety of GS-9674 as Assessed By Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs),"TEAEs were defined as 1 or both of the following: 1) Any adverse events (AE) with an onset date on or after the study drug start date and no later than 30 days after permanent discontinuation of study drug, 2) Any AEs leading to premature discontinuation of study drug.",Up to 24 weeks plus 30 days,Overall Safety of GS-9674 as Assessed By Percentage of Participants With Treatment-Emergent Laboratory Abnormalities,"Treatment-emergent laboratory abnormalities are defined as values that increase at least 1 toxicity grade from baseline at any post-baseline time point, up to and including the date of last dose of study drug plus 30 days for participants who permanently discontinued study.",Up to 24 weeks plus 30 days,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
41,Number of Participants With Treatment-related Adverse Events.,"The safety of Oral Insulin will be measured by the number of treatment-related adverse events according to CTCAE version 5.0

A biostatistician reviewed the study data and determined that it is of poor quality and cannot be appropriately analyzed.

Conclusions about this study cannot be made based on the study data.",Week -6 through Week 12 inclusive,,,,,,,,,,,,,,,,,,,,,,,,,Change From Screening in Liver Fat Content as Measured by MRI Proton Density Fat Fraction (MR PDFF),"The change in liver fat content measured by MRI-Proton Density Fat Fraction from week -6 to week 12 MR PDFF is expressed as a fat percentage in the liver.

Change in MR PDFF = MR PDFF (week 12) - MR PDFF( Screening)

A biostatistician reviewed the study data and determined that it is of poor quality and cannot be appropriately analyzed.

Conclusions about this study cannot be made based on the study data.",Week -6 (screening) and Week 12,Change From Screening in Liver Fibrosis (Elasticity),"Change from screening in Mean Transient Elasticity (Fibrosis) measured in kPA (kilo Pascal).

A biostatistician reviewed the study data and determined that it is of poor quality and cannot be appropriately analyzed.

Conclusions about this study cannot be made based on the study data.",Week -6 (Screening) and Week 12,Change From Screening in Liver Steatosis,"Change in liver steatosis as measured by FibroScan Controlled Attenuation Parameter (CAP) in units of dB/meter. Mean fibrosis score (severity scale of liver fibrosis) measured at screening (week -6) and week 12. Fibrosis Score CAP measures the steatosis (fatty change) in the liver. The CAP score is measured in decibels per meter (dB/m). It ranges from 100 to 400 dB/m, with higher values indicating more fatty change.

A biostatistician reviewed the study data and determined that it is of poor quality and cannot be properly analyzed.

Conclusions about this study cannot be made based on the study data.",Week -6 and Week 12,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
42,Evaluation of Safety and Tolerability - Treatment-emergent Adverse Events,Summary of treatment emergent adverse events coded using MedDRA,12 weeks,,,,,,,,,,,,,,,,,,,,,,,,,Evaluation of Pharmacokinetics - PK,Peak plasma concentration of SGM-1019 as measured by Cmax,12 weeks,Evaluation of Pharmacodynamics - Labs,"Evaluation of liver functions labs of ALT, AST, ALP, and bilirubin.",12 weeks,Evaluation of Phamacodynamics - MRI,"Evaluation of MRI parameters for assessment of liver fat, fibroinflammation, and stiffness.",12 weeks,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
43,Subject incidence of adverse events for TERN-201 versus placebo,,16 weeks,,,,,,,,,,,,,,,,,,,,,,,,,Plasma concentration of TERN-201- AUC,Area under the curve,12 weeks,Plasma concentration of TERN-201- Cmax,Maximum observed concentration,12 weeks,Plasma concentration of TERN-201- Tmax,Time to reach maximum measured plasma concentration,12 weeks,Plasma concentration of TERN-201- T1/2,Determination of half-life,12 weeks,Percent Change from baseline in plasma VAP-1/SSAO activity,,12 weeks,Urine concentration of TERN-201- CLr,Renal clearance,Day 1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
44,Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs),"Treatment-emergent adverse events (TEAEs) were defined as, any AEs with an onset date on or after the study drug start date and no later than 30 days after permanent discontinuation of study drug or any AEs leading to premature discontinuation of study drug. Participants were assessed for AEs according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.",First dose date up to Week 24 plus 30 days,Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities,"Treatment-emergent laboratory abnormalities, defined as values that increase at least one toxicity grade from baseline at any time post-baseline up to and including the date of last dose of study drug plus 30 days, were summarized by treatment group. Graded laboratory abnormalities were defined using the grading scheme in the CTCAE 5.0.",First dose date up to 24 weeks plus 30 days,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
45,MRI-PDFF,To assess the changes in liver steatosis through magnetic resonance imaging (MRI) proton density fat fraction (PDFF) from baseline to Week 12,Week 12,Adverse events,To evaluate the safety and tolerability of CS0159 in patients with NASH treated over 12 weeks,Week 12,,,,,,,,,,,,,,,,,,,,,,Cmax,maximum concentration (Cmax) from baseline to Week 12,"week 6, week 12",tmax,time to maximum plasma concentration (tmax) from baseline to Week 12,"week 6, week 12",t1/2,half-life (t1/2) from baseline to Week 12,"week 6, week 12",AUC,accumulation ratio of area under the concentration-time curve (AUC) in plasma from baseline to Week 12,"week 6, week 12",Pharmacodynamics (PD),Plasma concentrations and PD parameters of the biomarkers of FXR target engagement fibroblast growth factor 19 and 7α-hydroxy-4-cholesten-3-one (C4) from baseline to Week 12,"week 6, week 12",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
46,Resolution of NASH,Relieve clinical symptoms and prevent progression,3 months,,,,,,,,,,,,,,,,,,,,,,,,,Normalization of hepatic aminotransferases(ALT and AST),ALT and AST return to normal values,3 months,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
47,"Relative change from baseline in MRI-PDFF at Week 12 for TERN-501 monotherapy (Arms 1, 2 and 3) compared to placebo",,12 weeks,,,,,,,,,,,,,,,,,,,,,,,,,"Change from baseline in cT1 relaxation time at Week 12 for TERN-501 monotherapy (Arms 1, 2 and 3) compared to placebo",,12 weeks,Relative change from baseline in MRI-PDFF at Week 12 for TERN-501+TERN-101 combination (Arms 4 and 5) compared to placebo,,12 weeks,Change from baseline in cT1 relaxation time at Week 12 for TERN-501+TERN-101 combination (Arms 4 and 5) compared to placebo,,12 weeks,Patient incidence of treatment emergent adverse events for all treatment groups,,16 weeks,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
48,"To evaluate the effect of Saroglitazar Magnesium 4 mg compared with Placebo in improving NASH, defined as an improvement of at least 2 points (without worsening of fibrosis) in the NAFLD activity score (NAS)","Proportion of participants with at least 2-points improvement in NAS with at least 1-point improvement in either ballooning or inflammation and no worsening of liver fibrosis. Lower the scores, better the outcome.",From Baseline to Week 72,,,,,,,,,,,,,,,,,,,,,,,,,To evaluate the effect of Saroglitazar Magnesium 4 mg compared with Placebo on resolution of steatohepatitis and no worsening of liver fibrosis on the NASH Clinical Research Network (CRN) Histologic Scoring System,"Proportion of participants achieving resolution of steatohepatitis with no worsening of fibrosis. Lower the scores, better the outcome.",From Baseline to Week 72,To evaluate the effect of Saroglitazar Magnesium 4 mg compared with Placebo on improvement in fibrosis assessed by NASH CRN Histologic Scoring System with no worsening of steatohepatitis,"Proportion of participants achieving improvement in liver fibrosis (reduction of at least one stage) with no increase in NAS for ballooning, inflammation or steatosis. Lower the scores, better the outcome.",From Baseline to Week 72,To evaluate the effect of Saroglitazar Magnesium 4 mg compared with Placebo on changes in histological scores,"Number of participants with change in steatosis, ballooning, lobular inflammation, portal inflammation and fibrosis. Lower the scores, better the outcome.",From Baseline to Week 72,"To evaluate the effect of Saroglitazar Magnesium 4 mg compared with Placebo on changes in Liver Stiffness Measurement (LSM), Continuous Controlled Attenuation Parameter (CAP) and Fibroscan-AST (FAST) score, as measured by FibroScan®/VCTE","Number of participants with change in LSM, CAP, and FAST scores",From Baseline to Week 72,To evaluate the effects of Saroglitazar Magnesium 4 mg compared with Placebo on changes in non invasive markers of fibrosis and steatosis,"Number of participants with change in enhanced liver fibrosis (ELF) score, plasma pro-collagen type 3 (PRO-C3) levels, Fibrosis-4, AST to Platelet Ratio Index (APRI), and NAFLD Fibrosis Score (NFS)",From Baseline to Week 72,To evaluate the effect of Saroglitazar Magnesium 4 mg compared with Placebo on body weight,Number of participants with change in body weight,From Baseline to Week 72,"To evaluate the effect of Saroglitazar Magnesium 4 mg compared with Placebo on changes in 10-year Atherosclerotic cardiovascular disease (ASCVD) risk score (ACC/AHA Guideline on the Assessment of Cardiovascular Risk, 2013)",Number of participants with change in 10-year ASCVD risk score,From Baseline to Week 72,To evaluate the effect of Saroglitazar Magnesium 4 mg compared with Placebo on changes in health-related quality of life scores measured by SF-36 Questionnaire,"Number of participants with change in SF-36 Questionnaire, mental (MCS) and physical components scores (PCS)",From Baseline to Week 72,To evaluate the effect of Saroglitazar Magnesium 4 mg compared with Placebo on body mass index (BMI),From Baseline to Week 72,To evaluate the effect of Saroglitazar Magnesium 4 mg compared with Placebo on hip circumference,From Baseline to Week 72,To evaluate the effect of Saroglitazar Magnesium 4 mg compared with Placebo on minimum waist circumference,Number of participants with change in minimum waist circumference,From Baseline to Week 72,,,,,Number of participants with change in body mass index (BMI),,,Number of participants with change in hip circumference,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,To assess the safety and tolerability of Saroglitazar Magnesium 4 mg compared with placebo,"Number of participants with Treatment-Emergent Adverse Events (TEAE), Serious Adverse Events (SAEs), and Adverse Events of Special Interest (AESI)",From baseline to Week 72,To evaluate the safety and tolerability of Saroglitazar Magnesium 4 mg compared with Placebo,"Number of participants with abnormal Clinical laboratory testing of hematology, clinical chemistry, and urinalysis",From baseline to Week 72,Evaluate the safety and tolerability of Saroglitazar Magnesium 4 mg compared with Placebo,Number of participants with abnormal vital signs and physical examination,From baseline to Week 72,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
49,Histological Improvement of at Least 2 Points in NAFLD Activity Score (NAS) on Liver Biopsy After One Year.,"The NAFLD Activity Score (NAS) grades NAFLD on liver biopsy based on the individual scoring of steatosis, inflammation and balloning. The NAS is assessed on a scale of 0 to 8 with higher scores indicating more severe disease and lower scores indicating less severe disease. NAS is obtained by adding steatosis(assessed on a scale of 0 to 3), inflammation (assessed on a scale of 0 to 3) and ballooning (assessed on a scale of 0 to 2).","1 year (Baseline liver biopsy done at study entry, and subsequent liver biopsy done after one year of therapy with pentoxifylline or placebo)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
50,Parts A and B: Frequency of Adverse Events,,Part A: Up to 3.5 months; Part B: up to 12.5 months,Part C: Change from Baseline of Liver Hydroxysteroid 17β Dehydrogenase 13 (HSD17B13) Messenger Ribonucleic Acid (mRNA),,Baseline and Month 6,,,,,,,,,,,,,,,,,,,,,,Part A: Area Under the Plasma Concentration-time Curve (AUC) for ALN-HSD and Potential Metabolites,,Day 1 predose and up to 48 hours postdose,Pat A: Maximum Plasma Concentration (Cmax) for ALN-HSD and Potential Metabolites,,Day 1 predose and up to 48 hours postdose,Part A: Fraction Excreted in Urine (fe) of ALN-HSD and Potential Metabolites,,Day 1 up to 24 hours postdose,Part B: Plasma Concentrations of ALN-HSD and Potential Major Metabolite(s),,Day 1 and Month 3 predose and up to 4 hours postdose,Part B: Change from Baseline of Liver HSD17B13 mRNA,Hepatic HSD17B13 mRNA will be measured by quantitative reverse-transcription polymerase chain reaction using ribonucleic acid (RNA) isolated from liver biopsy.,Predose and up to 9 months postdose,Part C: Frequency of Adverse Events,,Up to 6 months,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
51,Percentage of Participants Who Achieved a ≥ 1-Stage Improvement in Fibrosis According to the Nonalcoholic Steatohepatitis (NASH) Clinical Research Network (CRN) Classification Without Worsening of NASH at Week 48,"Fibrosis improvement was defined as ≥ 1-stage decrease from baseline in fibrosis according to the NASH CRN classification. NASH CRN fibrosis stages range from 0 to 4, with higher scores indicating greater fibrosis (0=None, 4=Cirrhosis). Worsening of NASH was defined as ≥ 1 point increase from baseline in hepatocellular ballooning or lobular inflammation according to the Non-Alcoholic Fatty Liver Disease (NAFLD) Activity Score (NAS) criteria. As defined by NAS, hepatocellular ballooning ranges from 0-2 and lobular inflammation ranges from 0-3, with higher scores indicating more severe hepatocellular ballooning or lobular inflammation.",Week 48,Event-Free Survival (EFS) at Week 240 as Assessed by Time to First Clinical Event,"EFS was assessed by the time to the first clinical event, including progression to cirrhosis on liver biopsy, liver decompensation events, liver transplantation, and all-cause mortality.",Week 240,,,,,,,,,,,,,,,,,,,,,,Percentage of Participants Who Had Progression to Cirrhosis at Week 48,Progression to cirrhosis was defined as a change in NASH CRN fibrosis stage from \< 4 at baseline to 4 at Week 48.,Week 48,Percentage of Participants Who Had a ≥ 1-Stage Improvement in Fibrosis Without Worsening of NASH at Week 240,"Fibrosis improvement was defined as ≥ 1-stage decrease from baseline in fibrosis according to the NASH CRN classification. NASH CRN fibrosis stages range from 0 to 4, with higher scores indicating greater fibrosis (0=None, 4=Cirrhosis). Worsening of NASH was defined as ≥ 1 point increase from baseline in hepatocellular ballooning or lobular inflammation according to the NAS criteria. As defined by NAS, hepatocellular ballooning ranges from 0-2 and lobular inflammation ranges from 0-3, with higher scores indicating more severe hepatocellular ballooning or lobular inflammation.",Week 240,Percentage of Participants Who Had a ≥ 1-Stage Improvement in Fibrosis at Week 48,"Fibrosis improvement was defined as ≥ 1-stage decrease from baseline in fibrosis according to the NASH CRN classification. NASH CRN fibrosis stages range from 0 to 4, with higher scores indicating greater fibrosis (0=None, 4=Cirrhosis).",Week 48,Percentage of Participants Who Had a ≥ 1-Stage Improvement in Fibrosis at Week 240,"Fibrosis improvement was defined as ≥ 1-stage decrease from baseline in fibrosis according to the NASH CRN classification. NASH CRN fibrosis stages range from 0 to 4, with higher scores indicating greater fibrosis (0=None, 4=Cirrhosis).",Week 240,Percentage of Participants Who Had NASH Resolution Without Worsening of Fibrosis at Week 48,NASH resolution was defined as lobular inflammation of 0 or 1 from ≥ 1 at baseline and hepatocellular ballooning of 1 from a value ≥ 1 at baseline; both criteria were necessary conditions. Evaluable participants had baseline lobular inflammation and hepatocellular ballooning ≥ 1. Worsening of Fibrosis was defined by an increase in Fibrosis stage from 3 to 4 as defined by NASH CRN.,Week 48,Percentage of Participants Who Had NASH Resolution Without Worsening of Fibrosis at Week 240,NASH resolution was defined as lobular inflammation of 0 or 1 from ≥ 1 at baseline and hepatocellular ballooning of 1 from a value ≥ 1 at baseline; both criteria were necessary conditions. Evaluable participants had baseline lobular inflammation and hepatocellular ballooning ≥ 1. Worsening of Fibrosis was defined by an increase in Fibrosis stage from 3 to 4 as defined by NASH CRN.,Week 240,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
52,Percentage of Participants Who Achieve a ≥ 1-Stage Improvement in Fibrosis According to the Nonalcoholic Steatohepatitis (NASH) Clinical Research Network (CRN) Classification Without Worsening of NASH,"Fibrosis improvement was defined as ≥ 1-stage decrease from baseline in fibrosis according to the NASH CRN classification. NASH CRN fibrosis stages range from 0 to 4, with higher scores indicating greater fibrosis (0=None, 4=Cirrhosis). Worsening of NASH was defined as ≥ 1 point increase from baseline in hepatocellular ballooning or lobular inflammation according to the Non-Alcoholic Fatty Liver Disease (NAFLD) Activity Score (NAS) criteria. As defined by NAS, hepatocellular ballooning ranges from 0-2 and lobular inflammation ranges from 0-3, with higher scores indicating more severe hepatocellular ballooning or lobular inflammation.",Week 48,Event-Free Survival (EFS) at Week 240 as Assessed by Time to First Clinical Event,"EFS was assessed by the time to the first clinical event, including liver decompensation events, liver transplantation and all-cause mortality.",Week 240,,,,,,,,,,,,,,,,,,,,,,Percentage of Participants Who Had a ≥ 1-Stage Improvement in Fibrosis Without Worsening of NASH at Week 240,"Fibrosis improvement was defined as ≥ 1-stage decrease from baseline in fibrosis according to the NASH CRN classification. NASH CRN fibrosis stages range from 0 to 4, with higher scores indicating greater fibrosis (0=None, 4=Cirrhosis). Worsening of NASH was defined as ≥ 1 point increase from baseline in hepatocellular ballooning or lobular inflammation according to the NAS criteria. As defined by NAS, hepatocellular ballooning ranges from 0-2 and lobular inflammation ranges from 0-3, with higher scores indicating more severe hepatocellular ballooning or lobular inflammation.",Week 240,Percentage of Participants Who Had a ≥ 1-Stage Improvement in Fibrosis at Week 48,"Fibrosis improvement was defined as ≥ 1-stage decrease from baseline in fibrosis according to the NASH CRN classification. NASH CRN fibrosis stages range from 0 to 4, with higher scores indicating greater fibrosis (0=None, 4=Cirrhosis).",Week 48,Percentage of Participants Who Had a ≥ 1-Stage Improvement in Fibrosis at Week 240,"Fibrosis improvement was defined as ≥ 1-stage decrease from baseline in fibrosis according to the NASH CRN classification. NASH CRN fibrosis stages range from 0 to 4, with higher scores indicating greater fibrosis (0=None, 4=Cirrhosis).",Week 240,Percentage of Participants Who Had NASH Resolution at Week 48,"NASH resolution was defined as lobular inflammation of 0 or 1 from ≥ 1 at baseline and hepatocellular ballooning reduced to 0 from a value ≥ 1 at baseline; both criteria were necessary conditions. As defined by NAS, hepatocellular ballooning ranges from 0-2 and lobular inflammation ranges from 0-3, with higher scores indicating more severe hepatocellular ballooning or lobular inflammation. Evaluable participants had baseline lobular inflammation and hepatocellular ballooning ≥ 1.",Week 48,Percentage of Participants Who Had NASH Resolution at Week 240,"NASH resolution was defined as lobular inflammation of 0 or 1 from ≥ 1 at baseline and hepatocellular ballooning reduced to 0 from a value ≥ 1 at baseline; both criteria were necessary conditions.As defined by NAS, hepatocellular ballooning ranges from 0-2 and lobular inflammation ranges from 0-3, with higher scores indicating more severe hepatocellular ballooning or lobular inflammation. Evaluable participants had baseline lobular inflammation and hepatocellular ballooning ≥ 1.",Week 240,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
53,Percent (%) change from Baseline to Subject Study Endpoint evaluation in aminoalanine transaminase (ALT) level.,,2 or 3 months,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
54,Number of Participant With Hepatic Histological Improvement in NAS by ≥ 2 Points With at Least 1-Point Reduction in Either Lobular Inflammation or Hepatocellular Ballooning and no Concurrent Worsening of Fibrosis at Year 1,"Hepatic histological improvement in Nonalcoholic Fatty Liver Disease Activity Score (NAS) at Year 1 was defined as a decrease (improvement) in NAS by ≥ 2 with at least a 1-point reduction in either lobular inflammation or hepatocellular ballooning and with no concurrent worsening of fibrosis stage. The NAS was derived as the unweighted sum of steatosis (0 to 3), lobular inflammation (0 to 3), and hepatocellular ballooning (0 to 2) scores. The NAS ranges from 0-8 with the higher score indicating more aggressive disease. Evaluation of fibrosis stage was based on the nonalcoholic steatohepatitis clinical research network (NASH CRN) fibrosis staging system, which was scaled from 0 to 4 stages where, 0=None to 4=Cirrhosis. Worsening of fibrosis stage was defined as progression of NASH CRN fibrosis stage.",Year 1,,,,,,,,,,,,,,,,,,,,,,,,,Number of Participants With Complete Resolution of Steatohepatitis With no Concurrent Worsening of Fibrosis Stage and Improvement in Fibrosis by at Least 1 Stage (NASH CRN System) and no Worsening of Steatohepatitis at Year 1,"Complete resolution of steatohepatitis was defined as histopathologic interpretation of no fatty liver disease, or simple or isolated steatosis with no steatohepatitis. As per NASH CRN system, no worsening of steatohepatitis was defined as no worsening of lobular inflammation or hepatocellular ballooning grade. The evaluation of fibrosis stage associated with NASH was based on the NASH CRN fibrosis staging system which was scaled from 0 to 4 stages where, 0=None to 4=Cirrhosis.",Year 1,Number of Participants With Complete Resolution of Steatohepatitis With no Concurrent Worsening of Fibrosis Stage and Improvement in Fibrosis by at Least 1 Stage (NASH CRN System) and no Worsening of Steatohepatitis at Year 2,"Complete resolution of steatohepatitis was defined as histopathologic interpretation of no fatty liver disease, or simple or isolated steatosis with no steatohepatitis. As per NASH CRN system, no worsening of steatohepatitis was defined as no worsening of lobular inflammation or hepatocellular ballooning grade. The evaluation of fibrosis stage associated with NASH was based on the NASH CRN fibrosis staging system which was scaled from 0 to 4 stages where, 0=None to 4=Cirrhosis.",Year 2,Number of Participants With Complete Resolution of Steatohepatitis With no Concurrent Worsening of Fibrosis Stage at Year 1,"Complete resolution of steatohepatitis was defined as histopathologic interpretation of no fatty liver disease, or simple or isolated steatosis with no steatohepatitis. As per NASH CRN system, no worsening of steatohepatitis was defined as no worsening of lobular inflammation or hepatocellular ballooning grade. The evaluation of fibrosis stage associated with NASH was based on the NASH CRN fibrosis staging system which was scaled from 0 to 4 stages where, 0=None to 4=Cirrhosis.",Year 1,Number of Participants With Complete Resolution of Steatohepatitis With no Concurrent Worsening of Fibrosis Stage at Year 2,"Complete resolution of steatohepatitis was defined as histopathologic interpretation of no fatty liver disease, or simple or isolated steatosis with no steatohepatitis. As per NASH CRN system, no worsening of steatohepatitis was defined as no worsening of lobular inflammation or hepatocellular ballooning grade. The evaluation of fibrosis stage associated with NASH was based on the NASH CRN fibrosis staging system which was scaled from 0 to 4 stages where, 0=None to 4=Cirrhosis.",Year 2,Number of Participants With Improvement in Fibrosis by at Least 1 Stage (NASH CRN System) and no Worsening of Steatohepatitis at Year 1,"The evaluation of fibrosis stage associated with NASH was based on the NASH CRN Fibrosis Staging System which was scaled from 0 to 4 stages where, 0=None to 4=Cirrhosis. As per NASH CRN system, no worsening of steatohepatitis was defined as no worsening of lobular inflammation or hepatocellular ballooning grade.",Year 1,Number of Participants With Improvement in Fibrosis by at Least 1 Stage (NASH CRN System) and no Worsening of Steatohepatitis at Year 2,"The evaluation of fibrosis stage associated with NASH was based on the NASH CRN Fibrosis Staging System which was scaled from 0 to 4 stages where, 0=None to 4=Cirrhosis. As per NASH CRN system, no worsening of steatohepatitis was defined as no worsening of lobular inflammation or hepatocellular ballooning grade.",Year 2,"Number of Participants With Deaths, Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), TEAEs Leading Study Drug to Discontinuation","A TEAE was defined as any adverse event that started or worsened on or after the start of the study medication and up to 30 days after the discontinuation of the study medication. An SAE was defined as any untoward medical occurrence that, at any dose, results in death, was life threatening, requires hospitalization or results in prolongation of existing hospitalization, results in disability/incapacity, or was a congenital anomaly/birth defect.",Years 1 and 2,Number of Participants With Clinically Significant Changes in Vital Signs,"Vital signs included blood pressure, temperature, heart rate, and respiration rate. Vital signs were reviewed by the Investigator for clinically significant changes.",Years 1 and 2,Number of Participants With Clinical Laboratory Abnormalities,Years 1 and 2,Number of Participants With Clinically Abnormal in Electrocardiogram (ECG) Findings,Years 1 and 2,Number of Participants With Hepatic Histological Improvement in NAS at Year 2,"Hepatic histological improvement in NAS at Year 2 was defined as a decrease (improvement) in NAS by ≥ 2 with at least a 1-point reduction in either lobular inflammation or hepatocellular ballooning and with no concurrent worsening of fibrosis stage. The NAS was derived as the unweighted sum of steatosis (0 to 3), lobular inflammation (0 to 3), and hepatocellular ballooning (0 to 2) scores. The NAS ranges from 0-8 with the higher score indicating more aggressive disease.",Year 2,"Change From Baseline in the 3 Categorical Features of NAS (Steatosis, Lobular Inflammation, Hepatocellular Ballooning) at Year 1",Year 1,"Change From Baseline in the 3 Categorical Features of NAS (Steatosis, Lobular Inflammation, Hepatocellular Ballooning) at Year 2",Year 2,Grade 3-4 abnormal clinical laboratory values that occurred in ≥2% participants were reported. Criteria used for various parameters was:Fasting glucose Grade3:\>250 - 500 mg/dL and Grade4: \>500 mg/dL; Alanine aminotransferase(ALT)Grade3:\>5.0 - 20.0 ×Upper Limit of Normal(ULN)and Grade4:\>20.0 ×ULN; Aspartate aminotransferase(AST)Grade3: \>5.0 - 20.0 ×ULN and Grade4: \>20.0 ×ULN; Activated partial thromboplastin(APT)/Partial thromboplastin time(PTT)Grade3: \>2.5×ULN; Triglycerides Grade3 \>500 - 1000 mg/dL and Grade4: \>1000 mg/dL; Gamma-glutamyl transferase(GGT)Grade3: \>5.0 - 20.0 ×ULN and Grade4: \>20.0 ×ULN; Creatine kinase Grade 3: \>5.0 - 10.0 ×ULN and Grade4: \>10.0 ×ULN; Uric acid Grade3:(ULN - 10 mg/dL; ULN - 0.59 mmol/L) and Grade4: \>10 mg/dL; Amylase Grade3: \>2.0 - 5.0 ×ULN and Grade4: \>5.0 ×ULN; Lipase Grade3: \>2.0 - 5.0 xULN and Grade4: \>5.0 xULN; Phosphorus Grade3: \<2.0 - 1.0 mg/dL and Grade4: \<1.0 mg/dL and Absolute neutrophil Grade3: \<1.0 - 0.5 × 109/L and Grade4: \<0.5 × 109/L.,Number of Participants With Hepatic Histological Improvement With a Minimum 2-Point Improvement in NAS With at Least a 1-Point Improvement in More Than 1 Categorical Features of NAS and no Concurrent Worsening of Fibrosis Stage at Year 1,Year 1,A 12-lead ECG was performed. ECG results were reviewed by the Investigator for clinically notable abnormalities.,"NAS was calculated using the following 3 categorical features: steatosis which was scaled from 0-3 (steatosis score is defined as 0= \<5%, 1= 5 - 33%, 2= \>33 - 66%, and 3= \>66%), lobular inflammation which was scaled from 0-3 (lobular inflammation score defined as 0= no foci, 1= \< 2 foci/200x, 2= 2-4 foci/200x, and 3= \> 4 foci/200x), and hepatocellular ballooning which was scaled from 0-2 (hepatocellular ballooning score is defined as 0=none, 1=few balloon cells, 2=many cells/prominent ballooning). A negative change from Baseline indicates improvement.","NAS was calculated using the following 3 categorical features: steatosis which was scaled from 0-3 (steatosis score is defined as 0= \<5%, 1= 5 - 33%, 2= \>33 - 66%, and 3= \>66%), lobular inflammation which was scaled from 0-3 (lobular inflammation score defined as 0= no foci, 1= \< 2 foci/200x, 2= 2-4 foci/200x, and 3= \> 4 foci/200x), and hepatocellular ballooning which was scaled from 0-2 (hepatocellular ballooning score is defined as 0=none, 1=few balloon cells, 2=many cells/prominent ballooning). A negative change from Baseline indicates improvement.","Hepatic histological improvement in NAS was defined as a decrease (improvement) in NAS by ≥ 2 with at least a 1-point reduction in either steatosis, lobular inflammation or hepatocellular ballooning and with no concurrent worsening of fibrosis stage. The NAS was derived as the unweighted sum of steatosis (0 to 3), lobular inflammation (0 to 3), and hepatocellular ballooning (0 to 2) scores. The NAS ranges from 0-8 with the higher score indicating more aggressive disease. Worsening was defined as progression of NASH CRN fibrosis stage.",Number of Participants With Hepatic Histological Improvement With a Minimum 2-Point Improvement in NAS With at Least a 1-point Improvement in More Than 1 Categorical Features of NAS and no Concurrent Worsening of Fibrosis Stage at Year 2,"Hepatic histological improvement in NAS was defined as a decrease (improvement) in NAS by ≥ 2 with at least a 1-point reduction in either steatosis, lobular inflammation or hepatocellular ballooning and with no concurrent worsening of fibrosis stage. The NAS was derived as the unweighted sum of steatosis (0 to 3), lobular inflammation (0 to 3), and hepatocellular ballooning (0 to 2) scores. The NAS ranges from 0-8 with the higher score indicating more aggressive disease. Worsening was defined as progression of NASH CRN fibrosis stage.",Year 2,Number of Participants With Resolution of NASH Using a Modified Definition Based on Categorical Features of NAS and no Concurrent Worsening of Fibrosis Stage at Year 1,Resolution of NASH was defined as having no hepatocellular ballooning (grade 0) and minimal to no lobular inflammation (grade 1 or 0) with no concurrent worsening of fibrosis stage (worsening defined as progression of NASH CRN fibrosis stage).,Year 1,Number of Participants With Resolution of NASH Using a Modified Definition Based on Categorical Features of NAS and no Concurrent Worsening of Fibrosis Stage at Year 2,Resolution of NASH was defined as having no hepatocellular ballooning (grade 0) and minimal to no lobular inflammation (grade 1 or 0) with no concurrent worsening of fibrosis stage (worsening defined as progression of NASH CRN fibrosis stage).,Year 2,Change From Baseline in Morphometric Quantitative Collagen on Liver Biopsy at Year 1,The morphometric quantitative collagen on liver biopsy was determined as percent collagen area (PCA) using Sirius red stain on liver biopsy at Year 1. A negative change from Baseline indicates improvement.,Year 1,Change From Baseline in Morphometric Quantitative Collagen on Liver Biopsy at Year 2,The morphometric quantitative collagen on liver biopsy was determined as percent collagen area (PCA) using Sirius red stain on liver biopsy at Year 2. A negative change from Baseline indicates improvement.,Year 2,Change From Baseline in Hepatic Tissue Fibrogenic Protein Alpha-Smooth Muscle Actin (α-SMA) at Year 1,The hepatic tissue fibrogenic protein α-SMA level was determined as percent α-SMA + area using α-SMA stain on liver biopsy at Year 1. A positive change from Baseline indicates worsening.,Baseline (Day 1) to Year 1,Change From Baseline in Hepatic Tissue Fibrogenic Protein Alpha-Smooth Muscle Actin (α-SMA) at Year 2,The hepatic tissue fibrogenic protein α-SMA level was determined as percent α-SMA + area using α-SMA stain on liver biopsy at Year 2. A positive change from Baseline indicates worsening.,Baseline (Day 1) to Year 2,Change From Baseline in Morphometric Quantitative Fat Content on Liver Biopsy at Year 1,"The morphometric quantitative fat content was done to find out the amount of fat accumulated in the liver. A liver biopsy was performed to determine percent fat area, at Year 1. A negative change from Baseline indicates improvement.",Year 1,Change From Baseline in Morphometric Quantitative Fat Content on Liver Biopsy at Year 2,"The morphometric quantitative fat content was done to find out the amount of fat accumulated in the liver. A liver biopsy was performed to determine percent fat area, at Year 2. A negative change from Baseline indicates improvement.",Year 2,Change From Baseline in Histologic Fibrosis Stage (NASH CRN System and Ishak Scale Score) at Year 1,"The participant's histologic fibrosis stage was determined using the NASH CRN system and Ishak scale score assessment at Year 1. The evaluation of fibrosis stage associated with NASH was based on the NASH CRN Fibrosis Staging System which was scaled from 0 to 4 where, 0=None to 4=Cirrhosis. The histologic fibrosis stage based on the Ishak assessment was divided into 1 to 6 stages. Fibrosis was staged with the Ishak scale (ranging from 0=No fibrosis to 6=Cirrhosis). A positive change from Baseline indicates worsening.",Baseline (Day 1) to Year 1,Change From Baseline in Histologic Fibrosis Stage (NASH CRN System and Ishak Scale Score) at Year 2,"The participant's histologic fibrosis stage was determined using the NASH CRN system and Ishak scale score assessment at Year 1. The evaluation of fibrosis stage associated with NASH was based on the NASH CRN Fibrosis Staging System which was scaled from 0 to 4 where, 0=None to 4=Cirrhosis. The histologic fibrosis stage based on the Ishak assessment was divided into 1 to 6 stages. Fibrosis was staged with the Ishak scale (ranging from 0=No fibrosis to 6=Cirrhosis). A negative change from Baseline indicates improvement.",Baseline (Day 1) to Year 2,Change From Baseline in Portal Inflammation Grade on Liver Biopsy at Year 1,"Portal inflammation on liver biopsy was graded from 0 to 4 where 0= None, 1= Mild, 2= Moderate, and 3= Marked. A positive change from Baseline indicates worsening.",Baseline (Day 1) to Year 1,Change From Baseline in Portal Inflammation Grade on Liver Biopsy at Year 2,"Portal inflammation on liver biopsy was graded from 0 to 4 where 0= None, 1= Mild, 2= Moderate, and 3= Marked. A positive change from Baseline indicates worsening.",Baseline (Day 1) to Year 2,"Change From Baseline in Non-invasive Marker of Hepatic Fibrosis: Aspartate Aminotransferase to Platelet Count Ratio Index (APRI) at Months 3, 6 and 12","APRI is the ratio of aspartate aminotransferase (AST) to platelet count. It is calculated using formula, APRI = (AST level \[/ULN\] / platelet counts \[10\^9/L\]) \* 100. An APRI index of \<=0.50 indicated the absence of significant fibrosis and an index of \> 1.50 indicated the presence of significant fibrosis. A negative change from Baseline indicates decreased fibrosis.","Baseline (Month 0) to Months 3, 6 and 12","Change From Baseline in Non-invasive Marker of Hepatic Fibrosis: Aspartate Aminotransferase to Platelet Count Ratio Index (APRI) at Months 15, 18 and 24","APRI is the ratio of aspartate aminotransferase (AST) to platelet count. It is calculated using formula, APRI = (AST level \[/ULN\] / platelet counts \[10\^9/L\]) \* 100. An APRI index of \<=0.50 indicated the absence of significant fibrosis and an index of \> 1.50 indicated the presence of significant fibrosis. A negative change from Baseline indicates decreased fibrosis.","Baseline (Month 0) to Months 15, 18 and 24","Change From Baseline in Non-invasive Marker of Hepatic Fibrosis: Fibrosis-4 (FIB-4) at Months 3, 6 and 12","Fibrosis-4 is the ratio of age in years and aminotransferase to platelet count. It is a non-invasive hepatic fibrosis index score combining standard biochemical values, platelets, alanine aminotransferase (ALT), AST and age that is calculated using formula: FIB-4 = (Age \[years\] x AST \[U/L\]) / (platelets \[10\^9/L\] x (square root of ALT \[U/L\])). A FIB-4 index of \< 1.45 indicated no or moderate fibrosis and an index of \> 3.25 indicated extensive fibrosis/cirrhosis. A positive change from Baseline indicates increased fibrosis.","Baseline (Month 0) to Months 3, 6 and 12","Change From Baseline in Non-invasive Marker of Hepatic Fibrosis: Fibrosis-4 (FIB-4) at Months 15, 18 and 24","Fibrosis-4 is the ratio of age in years and aminotransferase to platelet count. It is a non-invasive hepatic fibrosis index score combining standard biochemical values, platelets, alanine aminotransferase (ALT), AST and age that is calculated using formula: FIB-4 = (Age \[years\] x AST \[U/L\]) / (platelets \[10\^9/L\] x (square root of ALT \[U/L\])). A FIB-4 index of \< 1.45 indicated no or moderate fibrosis and an index of \> 3.25 indicated extensive fibrosis/cirrhosis. A positive change from Baseline indicates increased fibrosis.","Baseline (Month 0) to Months 15, 18 and 24",Change From Baseline in Non-invasive Marker of Hepatic Fibrosis: Hyaluronic Acid at Months 6 and 12,Hyaluronic acid is a non-invasive hepatic fibrosis marker. A negative change from Baseline indicates decreased fibrosis.,Baseline (Month 0) to Months 6 and 12,Change From Baseline in Non-invasive Marker of Hepatic Fibrosis: Hyaluronic Acid at Months 18 and 24,Hyaluronic acid is a non-invasive hepatic fibrosis marker. A positive change from Baseline indicates increased fibrosis.,Baseline (Month 0) to Months 18 and 24,"Change From Baseline in Non-invasive Markers of Hepatic Fibrosis: Nonalcoholic Fatty Liver Disease (NAFLD) Fibrosis Score (NFS) at Months 3, 6 and 12","NFS is calculated using formula: NFS = -1.675 + 0.037 \* age (years) + 0.094 \* Body mass index (BMI) (kg/m\^2) + 1.13 \* Impaired fasting glucose (IFG)/diabetes (yes = 1, no = 0) + 0.99 \* Aspartate aminotransferase (AST)/ Alanine aminotransferase (ALT) ratio - 0.013 × platelet (\*10\^9/L) - 0.66 \* albumin (g/dL). A negative change from Baseline indicates decreased fibrosis.","Baseline (Month 0) to Months 3, 6 and 12","Change From Baseline in Non-invasive Markers of Hepatic Fibrosis: NAFLD Fibrosis Score (NFS) at Months 15, 18 and 24","NFS is calculated using formula: NFS = -1.675 + 0.037 \* age (years) + 0.094 \* Body mass index (BMI) (kg/m\^2) + 1.13 \* Impaired fasting glucose (IFG)/diabetes (yes = 1, no = 0) + 0.99 \* Aspartate aminotransferase (AST)/ Alanine aminotransferase (ALT) ratio - 0.013 × platelet (\*10\^9/L) - 0.66 \* albumin (g/dL). A negative change from Baseline indicates decreased fibrosis.","Baseline (Month 0) to Months 15, 18 and 24",Change From Baseline in Non-invasive Markers of Hepatic Fibrosis: Enhanced Liver Fibrosis Test (ELF) Score at Months 6 and 12,"The markers of fibrosis assessed in this test comprised hyaluronic acid (CHA), tissue inhibitor of metalloproteinase (CTIMP1) and procollagen III N-terminal peptide (CP3NP); these are components of the extracellular matrix and basement sinusoidal membrane of the liver and are elevated during activation of the stellate cell. The ELF tests were performed on Centaur device and the composite score was calculated as follows: ELF score = 2.278 + 0.851 ln(CHA) + 0.751 ln (CP3NP) + 0.394 ln(CTIMP1). ELF score \< 7.7: no to mild fibrosis; ≥ 7.7 - \< 9.8: Moderate fibrosis; ≥ 9.8 - \< 11.3: Severe fibrosis; ≥ 11.3: Cirrhosis. A negative change from Baseline indicates decreased fibrosis.",Baseline (Month 0) to Months 6 and 12,Change From Baseline in Non-invasive Markers of Hepatic Fibrosis: Enhanced Liver Fibrosis Test (ELF) Score at Months 18 and 24,"The markers of fibrosis assessed in this test comprised hyaluronic acid (CHA), tissue inhibitor of metalloproteinase (CTIMP1) and procollagen III N-terminal peptide (CP3NP); these are components of the extracellular matrix and basement sinusoidal membrane of the liver and are elevated during activation of the stellate cell. The ELF tests were performed on Centaur device and the composite score was calculated as follows: ELF score = 2.278 + 0.851 ln(CHA) + 0.751 ln (CP3NP) + 0.394 ln(CTIMP1). ELF score \< 7.7: no to mild fibrosis; ≥ 7.7 - \< 9.8: Moderate fibrosis; ≥ 9.8 - \< 11.3: Severe fibrosis; ≥ 11.3: Cirrhosis. A negative change from Baseline indicates decreased fibrosis.",Baseline (Month 0) to Months 18 and 24,"Change From Baseline in Biomarkers of Hepatocyte Apoptosis: Caspase Cleaved (CK-18 [M-30]) Levels and Total M-65 (CK-18 [M-65]) Levels at Months 3, 6 and 12",Caspase-cleaved cytokeratin levels (CK18M30) and total M-65 (CK-18 \[M-65\]) were measured as biomarkers of hepatocyte apoptosis. A negative change from Baseline indicates decreased hepatocyte apoptosis.,"Baseline (Month 0) to Months 3, 6 and 12","Change From Baseline in Biomarkers of Hepatocyte Apoptosis: Caspase Cleaved (CK-18 [M-30]) Levels and Total M-65 (CK-18 [M-65]) Levels at Months 15, 18 and 24",Caspase-cleaved cytokeratin levels (CK18M30) and total M-65 (CK-18 \[M-65\]) were measured as biomarkers of hepatocyte apoptosis. A negative change from Baseline indicates decreased hepatocyte apoptosis.,"Baseline (Month 0) to Months 15, 18 and 24","Change From Baseline in Weight at Months 3, 6 and 12",A negative change from Baseline represents decreased weight.,"Baseline (Day 1) to Months 3, 6 and 12","Change From Baseline in Weight at Months 15, 18 and 24",A negative change from Baseline represents decreased weight.,"Baseline (Day 1) to Months 15, 18 and 24","Change From Baseline in Body Mass Index (BMI) at Months 3, 6 and 12",The body mass index is a value derived from the mass (weight in kgs) and height (in centimeters) of an individual and is calculated as the body mass divided by the square of the body height. A negative change from Baseline represents decreased BMI.,"Baseline (Day 1) to Months 3, 6 and 12","Change From Baseline in Body Mass Index (BMI) at Months 15, 18 and 24",The body mass index is a value derived from the mass (weight in kgs) and height (in centimeters) of an individual and is calculated as the body mass divided by the square of the body height. A negative change from Baseline represents decreased BMI.,"Baseline (Day 1) to Months 15, 18 and 24","Change From Baseline in Waist Circumference at Months 3, 6 and 12",A negative change from Baseline represents decreased in waist circumference.,"Baseline (Day 1) to Months 3, 6 and 12","Change From Baseline in Waist Circumference at Months 15, 18 and 24",A negative change from Baseline represents decreased in waist circumference.,"Baseline (Day 1) to Months 15, 18 and 24","Change From Baseline in Hip Circumference at Months 3, 6 and 12",A negative change from Baseline represents decreased hip circumference.,"Baseline (Day 1) to Months 3, 6 and 12","Change From Baseline in Hip Circumference at Months 15, 18 and 24",A negative change from Baseline represents decreased hip circumference.,"Baseline (Day 1) to Months 15, 18 and 24","Change From Baseline in Forearm Circumference at Months 3, 6 and 12",A negative change from Baseline represents decreased forearm circumference.,"Baseline (Day 1) to Months 3, 6 and 12","Change From Baseline in Forearm Circumference at Months 15, 18 and 24",A negative change from Baseline represents decreased forearm circumference.,"Baseline (Day 1) to Months 15, 18 and 24","Change From Baseline in Tricep Skinfold Thickness at Months 3, 6 and 12",A negative change from Baseline represents decreased Tricep Skinfold Thickness.,"Baseline (Day 1) to Months 3, 6 and 12","Change From Baseline in Tricep Skinfold Thickness at Months 15, 18 and 24",A negative change from Baseline represents decreased Tricep Skinfold Thickness.,"Baseline (Day 1) to Months 15, 18 and 24",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
55,investigate adipokine dna polymorphism,to investigate adipokine gene polymorphism associated with prognosis of NAFLD patients,1 months,correlations,"to correlate between gene polymorphism and glycated hemoglobin, liver enzyme and obesity",1 month,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
56,Change in liver fat percentage measured by MRI-PDFF,Liver fat is measured by MRI-PDFF,"baseline, 24 weeks",Change in liver fibrosis measured by MRE,Liver fibrosis is measured by Magnetic Resonance Enterography,"baseline, 24 weeks",Change in visceral fat area measured by MRI,Visceral fat area is measured by MRI,"baseline, 24weeks",Changes in serum concentrations of ALT and AST,ALT and AST concentrations in serum are measured,"baseline, 24weeks",,,,,,,,,,,,,,,,Change in serum concentration of Pro-C3,Pro-C3 concentration in serum is measured,"baseline, 24weeks",Change in serum concentration of CK-18,CK-18 concentration in serum is measured,"baseline, 24weeks",Change in insulin sensitivity determined by HOMA-IR,Insulin sensitivity is determined by Homeostatic Model Assessment for Insulin Resistance,"baseline, 24weeks",Change in serum concentration of Leptin,Concentration of Leptin in serum is measured,"baseline, 24weeks",Changes in serum concentrations of ALT and AST,ALT and AST concentrations in serum are measured,"baseline, 8weeks, 16weeks",Changes in serum concentrations of TG and TC,Triglyceride and Total Cholesterol concentrations in serum are measured,"baseline, 8weeks, 16weeks, 24weeks",Change of NAFLD fibrosis score(NFS),NFS is measured,"baseline, 8weeks, 16weeks, 24weeks",Change in serum concentration of Ghrelin,Concentration of Ghrelin in serum is measured,"baseline, 24weeks",Change in serum concentration of Adiponection,"baseline, 24weeks",,,,,,,,,,Concentration of Adiponection in serum is measured,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
57,Change in absolute liver fat content as measured by MRI from Baseline to Week 24,,24 weeks,,,,,,,,,,,,,,,,,,,,,,,,,Change in percentage liver fat content as measure by MRI from Baseline to Week 24,,24 weeks,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
58,Concentration of platelet-leukocyte aggregates (evaluated as median fluorescence intensity -MFI- of platelets bound to leukocytes) in whole blood in patients with NAFLD and NASH,"Platelet leukocyte aggregates are a sensitive surrogate marker of platelet activation. The level of platelet-leukocyte aggregates will be measured directly in anticoagulated whole blood, within 30 minutes from withdrawal. By multicolor flow cytometry the investigators will detect the percentage of leukocyte that stain positive for CD41a, a specific marker platelets. The investigators expect to detect a relevant difference in platelet-leukocytes aggregates of 10% between NASH and NAFLD patients.",1 year,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
59,Percentage of Participants Who Achieve ≥ 1-Stage Improvement in Fibrosis According to the NASH Clinical Research Network (CRN) Classification Without Worsening of NASH in Participants Treated With SEMA + CILO/FIR Versus Placebo,Worsening of NASH is defined as a ≥ 1-point increase in hepatocellular ballooning or lobular inflammation.,Week 72,,,,,,,,,,,,,,,,,,,,,,,,,Percentage of Participants Who Achieve ≥1-Stage Improvement in Fibrosis (According to the NASH CRN Classification) Without Worsening of NASH in Participants Treated With SEMA+CILO/FIR Versus SEMA Alone,Worsening of NASH is defined as a ≥ 1-point increase in hepatocellular ballooning or lobular inflammation.,Week 72,Percentage of Participants With NASH Resolution in Participants Treated with SEMA+CILO/FIR Versus Placebo,NASH resolution is defined as lobular inflammation of 0 or 1 and hepatocellular ballooning of 0.,Week 72,Percentage of Participants With NASH Resolution In Participants Treated With SEMA+CILO/FIR Versus CILO/FIR Alone,,Week 72,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
60,Assess the dose relationship of PK Parameter Cmax,"Following completion of each cohort, bioanalytical analyses for HU6, PK will be performed and plasma PK parameters for Cmax analyzed",3 months,Assess the dose relationship of PK Parameter AUC,"Following completion of each cohort, bioanalytical analyses for HU6, PK will be performed and plasma PK parameters for AUC analyzed",3 months,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
61,The Number of Participants with One or More Treatment-Emergent Adverse Events (TEAEs),,Part 1 SAD Cohorts: up to Day 26; Part 2 MAD Cohorts: up to Day 42,Pharmacokinetic (PK): Maximum observed concentration (Cmax) of ALT-801,,"Baseline, Day 26",Pharmacokinetic (PK): Area Under the Concentration (AUC) vs Time Curve of ALT-801,,Baseline to Day 26,Change in body weight,,Baseline to Week 6,Pharmacodynamic (PD): Change from baseline in magnetic resonance derived proton density fat fraction (MRI-PDFF),,Baseline to Week 6,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
62,Area Under the Plasma Concentration Versus Time Curve (AUC) of metformin and atorvastatin/warfarin and digoxin in presence of steady state ALT-801,,Baseline and Day 36,Area Under the Plasma Concentration Versus Time Curve (AUC) of ethinylestradiol and levonorgestrel in presence of steady state ALT-801,,Baseline and Day 43,,,,,,,,,,,,,,,,,,,,,,Cmax and Tmax of metformin and atorvastatin/warfarin and digoxin,,Day 36,Cmax and Tmax of ethinylestradiol and levonorgestrel,,Day 43,The Number of Participants with One or More Treatment-Emergent Adverse Events (TEAEs),,Up to Day 77,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
63,Omega-3 Fatty Acid Supplementation and Its Effect on Hepatic Steatosis and Other Factors Associated With the Development of Nonalcoholic Steatohepatitis (NASH),,24 weeks,,,,,,,,,,,,,,,,,,,,,,,,,Magnetic Resonance Imaging (MRI) as an Assessment of Hepatic Steatosis in Patients With Biopsy-proven Nonalcoholic Steatohepatitis (NASH),,24 weeks,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
64,Absolute Change in Hepatic Fat Fraction Based on MRI-PDFF Measurements in LPCN 1144 Treated Subjects Compared to Placebo.,The change in magnetic resonance imaging derived proton fat fraction (MRI-PDFF) from baseline to week 12 in LPCN 1144 treated subjects and subjects given placebo.,Baseline and Week 12,,,,,,,,,,,,,,,,,,,,,,,,,Relative Change in MRI-PDFF Measurements in LPCN 1144 Treated Subjects Compared to Placebo.,Requirement for inclusion in analysis was having a baseline hepatic fat fraction ≥ 5% based on MRI-PDFF.,Baseline and week 12,Number of Participants With Resolution of NASH on Overall Histopathological Reading in LPCN 1144 Treated Subjects Compared to Placebo,"Resolution of nonalcoholic steatohepatitis (NASH) is defined as the nonalcoholic fatty liver disease activity score (NAS) score of 0-1 for inflammation, 0 for ballooning, and any value for steatosis. These data are based on the NASH-clinical research network (CRN) histology scoring system. The range of scores are as follows (with higher scores equating to a more pathological feature): Steatosis 0-3, inflammation 0-3, ballooning 0-2, fibrosis state 0-4, and NAS 0-8.",Baseline and Week 36,Number of Subjects Achieving Resolution of NASH on Overall Histopathological Reading and no Worsening of Liver Fibrosis in LPCN 1144 Treated Subjects Compared to Placebo.,"Resolution of NASH is defined as NAS score of 0-1 for inflammation, 0 for ballooning, and any value for steatosis. These data are based on the NASH-CRN histology scoring system. The range of scores are as follows (with higher scores equating to a more pathological feature): Steatosis 0-3, inflammation 0-3, ballooning 0-2, fibrosis state 0-4, and NAS 0-8. No worsening was defined as a score in fibrosis equal to, or lower, than baseline.",Baseline and Week 36,Number of Subjects With Improvement in NASH Evaluated by Paired Biopsies Analysis and no Worsening of Liver Fibrosis in LPCN 1144 Treated Subjects Compared to Placebo.,"Paired biopsies are randomly assigned A or B and are scored by a blinded pathologist as better, worse or same for change in fibrosis, steatosis, inflammation, and ballooning. Improvement in NASH requires no worsening of fibrosis, an improvement in ballooning or inflammation, and no worsening of ballooning or inflammation. Assessment of better or same is considered as no worsening.",Baseline and week 36,Change in the Mean Score of NAS Components at Baseline and After 36 Weeks of Treatment in LPCN 1144 Treated Subjects Compared to Placebo.,"These data are based on the NASH-CRN histology scoring system. The range of scores are as follows (with higher scores equating to a more pathological feature): Steatosis 0-3, inflammation 0-3, ballooning 0-2, fibrosis state 0-4, and NAS 0-8.",Baseline and Week 36,Number of Subjects With an Improvement in Liver Fibrosis Greater Than or Equal to One Stage and no Worsening of NASH in LPCN 1144 Treated Subjects Compared to Placebo.,"These data are based on the NASH-CRN histology scoring system. The range of scores are as follows (with higher scores equating to a more pathological feature): Steatosis 0-3, inflammation 0-3, ballooning 0-2, and fibrosis stage 0-4. Improvement in liver fibrosis was defined as an improvement in fibrosis greater than or equal to one stage using the NASH CRN fibrosis score with no worsening of ballooning, inflammation, or steatosis.",Baseline and Week 36,Number of Subjects With Improvement in Fibrosis Evaluated by Paired Biopsies Analysis and no Worsening of NASH in LPCN 1144 Treated Subjects Compared to Placebo,"Paired biopsies are randomly assigned A or B and are scored by a blinded pathologist as better, worse or same for change in fibrosis, steatosis, inflammation, and ballooning. Improvement in fibrosis requires a better score in fibrosis and no worsening of ballooning or inflammation. Assessment of better or same is considered as no worsening.",Baseline to week 36,Number of Subjects With Improvement in Fibrosis Evaluated Via FibroNest Scores,"Improvement in Fibrosis is defined as improvement in parenchymal tissue normalized phenotypic fibrosis composite value compared to baseline. FibroNest is an image analysis system for the assessment of the severity and progression of fibrosis in NASH, produced by PharmaNest LLC.",Baseline and week 36,Relative Change in Appendicular Lean Muscle Mass,Baseline and 36 weeks,Relative Change in Whole Body Fat Mass,Baseline and week 36,Mean Change From Baseline in Liver Enzymes in LPCN 1144 Treated Subjects Compared to Placebo.,"Liver enzymes analyzed were aspartate transaminase (AST), alanine transaminase (ALT), alkaline phosphatase (ALP), and gamma-glutamyltransferase (GGT)",Baseline and Week 36,Mean Changes in Serum Lipid Profile Parameters in LPCN 1144 Treated Subjects Compared to Placebo.,Baseline and Week 36,,,Relative change in appendicular lean muscle mass measured by dual-energy absorptiometry (DXA) in LPCN 1144 treated subjects compared to Placebo. Data were last observation carried forward.,,,Relative change in whole body fat mass measured by dual-energy absorptiometry (DXA) in LPCN 1144 treated subjects compared to Placebo. Data were last observation carried forward.,"Lipid profile parameters included total cholesterol, low-density lipoprotein (LDL), high-density lipoprotein (HDL), and triglycerides.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
65,Measure the safety and tolerability of LPCN 1144 by assessing the number of treatment-related adverse events,Monitor the safety and tolerability of LPCN 1144,Baseline to Week 36,Measure the effect of LPCN 1144 on liver injury markers,Monitor the safety and tolerability of LPCN 1144,Baseline to Week 36,Measure the effect of LPCN 1144 on serum lipid panels,Monitor the safety and tolerability of LPCN 1144,Baseline to Week 36,Measure the effect of LPCN 1144 on hematology panels,Monitor the safety and tolerability of LPCN 1144,Baseline to Week 36,Measure the safety and tolerability of LPCN 1144 by assessing changes in patient-reported disease severity using the PGI-S questionnaire,Monitor the safety and tolerability of LPCN 1144,Baseline to Week 36,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
66,Proportion of participants achieving NASH resolution without worsening of fibrosis based on histology after 52 weeks treatment,To assess the effect of AZD2693 versus placebo on histological resolution of NASH in participants with non-cirrhotic NASH with fibrosis and PNPLA3 risk allele carriers after 52 weeks,after 52 weeks,,,,,,,,,,,,,,,,,,,,,,,,,Proportion of participants with at least one stage of liver fibrosis improvement with no worsening of NASH based on biopsy after 52 weeks treatment,To assess the effects of AZD2693 versus placebo on histological fibrosis improvement,after 52 weeks,Proportion of participants with ≥ 2-point improvement from baseline in NAS based on biopsy after 52 weeks treatment,To assess the effect of AZD2693 versus placebo on ≥ 2-point improvement in NAS,after 52 weeks,Proportion of participants with improvement in fibrosis by at least one stage based on biopsy after 52 weeks treatment,To assess the effect of AZD2693 versus placebo on improvement in fibrosis by at least one stage,after 52 weeks,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Number of participants with Adverse Events/Serious Adverse Events (AEs/SAEs) and abnormal laboratory test results,"Haematology, urinalysis, clinical chemistry and eGFR",64 weeks,Number of participants with Adverse Events/Serious Adverse Events (AEs/SAEs) and abnormal clinical test results,Vital signs and electrocardiogram (ECG) assessments,64 weeks,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
67,Percentage of Participants Who Experienced Adverse Events (AEs) and Graded Laboratory Abnormalities,,Baseline to Post-treatment Week 24,,,,,,,,,,,,,,,,,,,,,,,,,Pharmacokinetics of GS-9450 and its metabolites,"Pharmacokinetics (Cmax, Tmax, Cmin, λz, t1/2, AUCtau, Vdss/F, and CL/F) measured by plasma sampling",Weeks 2 and 4,Change from baseline in alanine aminotransferase (ALT),,Baseline to Week 4,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
68,Open label part: Kinetics of histological outcome measures,"The primary endpoints are the kinetics of the following histological outcome measures for treatment duration of 24, 48 and 72 weeks and potentially following a 2nd post-baseline biopsy at weeks 72 or 96 or 120, respectively:

* Improvement in Fibrosis defined as the Proportion (%) of subjects with improvement in liver fibrosis greater than or equal to one stage (NASH CRN fibrosis score) and no worsening of steatohepatitis (defined as no increase in NAS for ballooning, inflammation or steatosis)
* Resolution of NASH defined as the Proportion (%) of subjects with resolution of NASH (defined by ballooning of 0 and inflammation 0-1) and no worsening of liver fibrosis on NASH CRN fibrosis score (≥ 1 stage increase).",Up to 72 or 120 weeks,Double Blind Part: To evaluate the effect of Aramchol compared to placebo on liver histology by assessing the following primary endpoints:,"* Resolution of NASH defined as the Proportion (%) of subjects with resolution of NASH (defined by Ballooning of 0 and inflammation 0-1) and no worsening of liver fibrosis, or
* Improvement in Fibrosis defined as the Proportion (%) of subjects with improvement in liver fibrosis greater than or equal to one stage and no worsening of steatohepatitis.",72 weeks,Double Blind Part: To evaluate the effect of Aramchol compared to placebo on composite long-term outcome,"Proportion (%) of subjects experiencing at least 1 of the following events: All-cause mortality, Liver transplant, Histological progression to cirrhosis, MELD score \>15, Hospitalization due to hepatic decompensation event(s).","at End of Study, latest at 5 years from last subject's randomization",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
69,improvement in liver aminotransferases(ALT and AST),Difference between last and first measurements,6 months compared to the baseline,NAFLD fibrosis score (NFS),Change in NAFLD fibrosis score (NFS) (lower score means better outcome).,6 months compared to the baseline,,,,,,,,,,,,,,,,,,,,,,The Aspartate (AST) to Platelet Ratio Index (APRI) score:,Change in (APRI) score (lower score means better outcome).,6 months compared to the baseline,The Fibrosis-4 (FIB-4) values:,Change in (FIB-4) values (lower values means better outcome).,6 months compared to the baseline,Serum Alkaline Phosphatase level (ALP),Change in ALP serum level as inflammatory markers of NASH,6 months compared to the baseline,Serum Gamma-glutamyl Transferase level (GGT),Change in GGT serum level as inflammatory markers of NASH,6 months compared to the baseline,Serum total and direct bilirubin.,Change in levels of serum total and direct bilirubin.,6 months compared to the baseline,Waist circumference,Change in waist circumference,6 months compared to the baseline,Change in anthropometric measures,including BMI etc.,6 months compared to the baseline,Lipid profile,Change in serum lipids,6 months compared to the baseline,Glycated hemoglobin (HbA1C),6 months compared to the baseline,Fasting blood glucose level,6 months compared to the baseline,Drugs adverse events,Assessment of safety by reporting any adverse events,6 months compared to the baseline,,,,,Change in HbA1C level for patients with T2DM,,,Change in fasting blood glucose for patients with T2DM,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
70,Liver inflammation,ALT levels,6 months,,,,,,,,,,,,,,,,,,,,,,,,,Glucose metabolism,Insulin sensitivity using a 2-step clamp,6 months,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
71,Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs),,First dose date up to 48 weeks plus 30 days,Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities,Treatment-emergent laboratory abnormalities were defined as values that increase at least one toxicity grade from baseline. Participants with any laboratory abnormality were reported.,First dose date up to 48 weeks plus 30 days,Percentage of Participants Who Achieved a ≥ 1-Stage Improvement in Fibrosis Without Worsening of NASH at Week 48,Fibrosis improvement was defined as ≥ 1-stage decrease from baseline in fibrosis according to the NASH clinical research network classification (CRN) classification. Worsening of NASH was defined as ≥ 1-point increase from baseline in hepatocellular ballooning or lobular inflammation. The 95% CI was based on the Clopper-Pearson method.,Week 48,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
72,pharmacodynamic (PD) effect of HM15211,Proportion of subjects who achieve resolution of steatohepatitis on overall histopathological reading and no worsening of liver fibrosis,12 months,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
73,Proportion of participants achieving a histologic treatment effect (histologic response) as determined by the NASH CRN criteria after 24 weeks of NGM282 or matched placebo.,,24 weeks,Evaluate safety and tolerability of NGM282 in participants with NASH as a function of dose level after up to 24 weeks of treatment with NGM282.,,24 weeks,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
74,The Primary Outcome Will be Improvement in Hepatic Steatosis by Liver MRI,To examine the efficacy of Colesevelam at 3.75 g/day orally versus placebo to decrease liver fat in patients with biopsy-proven nonalcoholic steatohepatitis.,24 weeks,,,,,,,,,,,,,,,,,,,,,,,,,Insulin Sensitivity as Determined by HOMA-IR,To examine the efficacy of Colesevelam at 3.75 g/day orally versus placebo to decrease HOMA-IR in patients with biopsy-proven nonalcoholic steatohepatitis.,24 weeks,Serum ALT and AST Values,To examine the efficacy of Colesevelam at 3.75 g/day orally versus placebo to decrease serum ALT and AST in patients with biopsy-proven nonalcoholic steatohepatitis.,24 weeks,Lipid Profiles,To examine the efficacy of Colesevelam at 3.75 g/day orally versus placebo to decrease improve the lipid profiles in patients with biopsy-proven nonalcoholic steatohepatitis.,24 weeks,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
75,Two point change in histological NAFLD activity score (NAS),"Non-alcoholic fatty liver disease score (NAS) is a histological classification to assess the severity of liver steatosis, lobular inflammation and ballooning in the liver biopsy, which ranges from 0-8 with the increase in number representing a worse outcome. Therefore, the efficacy improvement was to be at least 2 points in lowering the score.","Baseline, 24 weeks",Proportion of subjects with at least a 30% change in % steatosis relative to screening,"Liver steatosis is graded based on the percentage of fat within the hepatocytes: grade 0 (healthy, \<5%), grade 1 (mild, 5%-33%), grade 2 (moderate, 34%-66%), and grade 3 (severe, \>66%). the efficacy improvement was to be proportion of subjects with at least a 30% decrease in % steatosis relative to screening.","Baseline, 24 weeks",,,,,,,,,,,,,,,,,,,,,,Change in the mean concentration of serum aspartate aminotransferase (AST),,"0, 2, 4, 6, 11, 24 weeks",Change in the mean concentration of serum alanine aminotransferase (ALT),,"0, 2, 4, 6, 11, 24 weeks",Change in liver histological fibrosis staging,"Fibrosis staging was measured as following criteria: 0=none, 1=perisinusoidal or periportal fibrosis, 2=perisinusoidal and portal/periportal fibrosis, 3=bridging fibrosis, and 4=cirrhosis.the definition of fibrosis stages improvement requires at least one stage.","Baseline, 24 weeks",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Change in the mean concentration of serum inflammation markers,"Change from baseline in Interleukin (IL)-6, C-reactive Protein (CRP).","0, 2, 4, 6, 11, 24 weeks",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
76,Improvement in scored liver histological improvement over 12 months,,Baseline to 12 months,,,,,,,,,,,,,,,,,,,,,,,,,Resolution of NASH,"defined as a hepatocellular ballooning score of 0, and lobular inflammation score of 0 or 1) without worsening of fibrosis",Baseline to 12 months,Improvement of fibrosis,defined as reduction in fibrosis of at least 1 stage) without worsening of NASH,Baseline to 12 months,Change in fibrosis score,,Baseline to 12 months,Change in each component score in the NAS,,Baseline to 12 months,Change in body weight,,Baseline to 12 months,Change in waist circumference,,Baseline to 12 months,Change in visceral fat,,Baseline to 12 months,Change in liver fat,,Baseline to 12 months,Change in HbA1C,Baseline to 12 months,Change in blood pressure,Baseline to 12 months,Change in serum lipids,,Baseline to 12 months,Change in insulin resistance,Baseline to 12 months,Change in inflammatory markers of NASH,Baseline to 12 months,,Change in health related quality of life scores (SF-36),Baseline to 12 months,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
77,NasH in relation to visceral and subcutaneous fat,Visceral fat volumetryusing MSCT and it'srelation tovisceral andsubcutaneous fat,base line,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
78,Liver Fat,Relative change in liver fat content (assessed by MRI-PDFF) from baseline to Week 12 in subjects treated with VK2809 compared to the change in subjects treated with placebo.,12 weeks,,,,,,,,,,,,,,,,,,,,,,,,,NASH CRN fibrosis score,Proportion of subjects with resolution of steatohepatitis on overall histopathological reading and no worsening of liver fibrosis on NASH CRN fibrosis score.,52 weeks,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
79,The Number of Participants With a 30% Reduction in Alanine Aminotransferase (ALT) Treated With Pentoxifylline (PTX) or Placebo for 12 Months.,The primary goal of the study was to determine whether pentoxifylline (PTX) therapy improved serum ALT (\> or = 30% change from baseline to month 12) compared to placebo.,baseline and 12 months,,,,,,,,,,,,,,,,,,,,,,,,,The Effect of Pentoxifylline on Change in Tumor Necrosis Factor [TNF]-α Levels in Patients With NASH,"The mean change from baseline to month 12 in proinflammatory cytokines (such as TNF-α) and gene expresssion were the secondary endpoints and were analyzed with the same analysis of covariance model and summary statistics specified for the primary endpoint. Differences were regarded as statistically significant when P \< 0.05. The results for TNF-α are reported here. Interleukin-6 \[IL-6\], IL-10) and expression of TNF-alpha Receptors (p55 and p75) had insufficient data for statistical analysis.",one year,Change in Serum Leptin Levels in Patients Treated With Pentoxifylline or Placebo for 12 Months,Values represent changes in leptin from baseline to 12 months in patients treated with pentoxifylline or placebo.,baseline and one year,Change in Serum Adiponectin Levels in Patients Treated With Pentoxifylline or Placebo for 12 Months,,one year,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
80,Analysis of MRI-PDFF Change From Baseline to Week 24 (Per Protocol Population),,Baseline to week 24,Analysis of MRI-PDFF Change From Baseline to Week 12 (Per Protocol Population),,Baseline to Week 12,,,,,,,,,,,,,,,,,,,,,,Analysis of ALT Change From Baseline to Week 24 (Per Protocol Population),,Baseline to week 24,Analysis of ALT Change From Baseline to Week 12 (Per Protocol Population),,Baseline to week 12,Time to Remission (in Weeks),"Time to remission is the time in weeks from randomization to liver function remission, defined as two consecutive ALT values within normal range (\<40 U/L) during the treatment period.",24 weeks,Change in BMI (Body Mass Index),,"Baseline, week 24",Change in Hemoglobin A1C,,"Baseline, week 24",Change in Homeostatic Model Assessment of Insulin Resistance (HOMA-IR),HOMA-IR was calculated according to the formula: fasting insulin (microU/L) x fasting glucose (nmol/L)/22.5. Optimal Range: 1.0 (0.5-1.4). Lower values represent a better outcome.,"Baseline, week 24",Percent Change in Cholesterol,,"Baseline, week 24",Percent Change in Triglycerides,,"Baseline, week 24",Percent Change in Low Density Lipoprotein (LDL) Cholesterol,"Baseline, week 24",Percent Change in High Density Lipoprotein (HDL),"Baseline, week 24",Mean Serum Aspartate Aminotransferase (AST),,"weeks 4, 8, 12, 16, 20, and 24",Mean Serum Alanine Aminotransferase (ALT),"weeks 4, 8, 12, 16, 20, and 24",Mean Serum Gamma-glutamyl Transpeptidase (GGT),"weeks 4, 8, 12, 16, 20, and 24",,Number of Subjects With ALT in Normal Range at Week 24,Week 24,,,,Normal range is \<40 U/L,Maximum Observed Concentrations (Cmax),,"pre-dose and at 0.25, 0.5, 0.75, 1.0, 1.5, 2.0, 3.0, 4.0, 6.0, 8.0, 10, 12, and 24 hours",Minimum Observed Concentration (Cmin),,"pre-dose and at 0.25, 0.5, 0.75, 1.0, 1.5, 2.0, 3.0, 4.0, 6.0, 8.0, 10, 12, and 24 hours",Area Under Concentration-time (AUC),,"pre-dose and at 0.25, 0.5, 0.75, 1.0, 1.5, 2.0, 3.0, 4.0, 6.0, 8.0, 10, 12, and 24 hours",Half-life,,"pre-dose and at 0.25, 0.5, 0.75, 1.0, 1.5, 2.0, 3.0, 4.0, 6.0, 8.0, 10, 12, and 24 hours",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
81,The Area under receiver operating characteristic (ROC) curve (AUC) of the LLIFT (Lille LIver Fat Test)-NASH score,"The variables constituting the calculation algorithm are : clinical data (age, gender, BMI, diabetes status), biological data (AST, ALT, GCT, fasting glucose, HbA1c, triglyceride,...) and genetic polymorphism",Baseline,,,,,,,,,,,,,,,,,,,,,,,,,The Area under receiver operating characteristic (ROC) curve (AUC) of the LLIFT (Lille LIver Fat Test)- steatosis score,"The variables constituting the algorithm are : clinical data (age, gender, BMI, diabetes status), biological data (AST, ALT, GCT, fasting glucose, HbA1c, triglyceride,..), genetic polymorphism.",Baseline,Assessment of the correlation between the LLIFT score and the NAS score,"The NAS score is a stratification based on steatosis, ballooning and lobular inflammation.",Baseline,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
82,To assess the safety and tolerability of long-term L-alanine supplementation and the therapeutic efficacy of long-term L-alanine supplementation by evaluating liver biochemistry and histological findings.,,1 year,,,,,,,,,,,,,,,,,,,,,,,,,"Determine the effect of L-alanine on gene profiles, anti-oxidant response and inflammatory response in hepatocytes. Evaluate possible correlation between therapeutic efficacy and gene profiles altered by L-alanine supplementation",,1 year,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
83,Liver fibrosis scores I-IV (METAVIR),"METAVIR fibrosis scores:

I = mild fibrosis II = significant fibrosis III = advanced fibrosis IV = cirrhosis",,,,,,,,,,,,,,,,,,,,,,,,,,Steatosis fibrosis scores I-III,"Steatosis scores:

0 = \<5% I = 5-33% II = 33-66% III = \>66%",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
84,Mean Change in Liver Fibrosis of Corrected T1 (cT1) Mapping (LiverMultiScan -LMS),"Difference in baseline adjusted mean change in liver fibrosis of corrected T1 (cT1) mapping with LiverMultiScan (LMS).

LiverMultiScan is CE marked as a class IIa medical device. Corrected T1 (cT1) is a Magnetic Resonance (MR) relaxation parameter/measure from the device.The measure cT1 can be compared across different Magnetic Resonance Imaging (MRI) systems and sites. It is an emerging biomarker for rapid quantification of hepatic fibro-inflammatory disease. In unhealthy tissue, such as in inflamed and fibrotic tissues, measures result in longer cT1-relaxation.",16 weeks,,,,,,,,,,,,,,,,,,,,,,,,,Baseline-adjusted Change in Liver Stiffness With MR-elastography (MRE),"Baseline-adjusted change in liver stiffness as measured by MR-elastography. Magnetic resonance elastography (MRE) is a technology that uses MRI imaging with low-frequency vibrations to create a visual map (elastogram) that shows stiffness of body tissues. Currently, MRE is used to detect stiffening of the liver caused by fibrosis and inflammation in chronic liver disease. Liver stiffness increases with liver damage/disease.",16 weeks,Baseline-adjusted Change in Liver Stiffness by FibroScan®,Baseline-adjusted change in liver stiffness as measured by FibroScan® scores. FibroScan measures scarring by measuring the stiffness of your liver. The fibrosis result is measured in kilopascals (kPa). It's normally between 2 and 6 kPa. Many people with liver disease(s) have a result that's higher than the normal range.,16 weeks,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
85,Change in liver stiffness measurement (LSM),LSM will be assessed by Fibro scan,At baseline and 12th week,Change in ultrasound score,Ultrasound score will be assessed by Ultrasonography,At baseline and 12th week,,,,,,,,,,,,,,,,,,,,,,Demonstrate changes in Alanine aminotransferase (ALT),Alanine aminotransferase (ALT) in U/L,At baseline and 12th week,Demonstrate changes in Aspartate aminotransferase (AST),Aspartate aminotransferase (AST) in U/L,At baseline and 12th week,Demonstrate changes in Alkaline phosphatase (ALP),Alkaline phosphatase (ALP) in U/L,At baseline and 12th week,Demonstrate changes in ɤ-glutamyltranspeptidase (GGT),ɤ-glutamyltranspeptidase (GGT) in U/L,At baseline and 12th week,Demonstrate changes in Direct bilirubin,Direct bilirubin in mg/dl,At baseline and 12th week,Demonstrate changes in the Lipid values,"Total cholesterol(TC) in mg/dl , Triglycerides(TG) in mg/dl , LDL-Cholesterol in mg/dl , HDL-Cholesterol in mg/dl",At baseline and 12th week,Demonstrate changes in the body weight and body mass index (BMI),BMI in kg/m\^2 will be calculated using the formula: BMI= \[Weight (kg)/Height (m2)\].,At baseline and 12th week,Demonstrate changes in the Inflammatory marker : CRP,C-reactive protein in mg/L,At baseline and 12th week,Demonstrate changes in Serum cytokeratin 18 (Ck-18),At baseline and 12th week,Demonstrate changes in Serum transforming growth factor-beta1 (TGF-β1),At baseline and 12th week,Serum Retinol binding protein 4 (RBP-4),Serum Retinol binding protein 4 (RBP-4) will be determined by Enzyme-linked Immunosorbent assay kits.,At baseline and 12th week,,,,,Serum cytokeratin 18 (Ck-18) will be determined by Enzyme-linked Immunosorbent assay kits.,,,Serum transforming growth factor-beta1 (TGF-β1) will be determined by Enzyme-linked Immunosorbent assay kits.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
86,Percentage of Participants With Nonalcoholic Steatohepatitis (NASH) Resolution Without Worsening of Fibrosis After 52 Weeks,"The NASH Clinical Research Network (CRN) scoring system evaluated by Blinded Independent Central Review (BICR) was used to assess treatment response. The NASH CRN scoring scales were: lobular inflammation score (0-3); hepatocyte ballooning score (0-2); steatosis score (0-3); and fibrosis score (0-4). NASH resolution was defined as a score of 0-1 for inflammation, 0 for ballooning, and any grade of steatosis.",Week 52,Percentage of Participants Who Experienced an Adverse Event (AE),"An adverse event (AE) was defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it was considered related to the medical treatment or procedure, that occurred during the course of the study.",Up to 64 weeks,Percentage of Participants Discontinuing Study Medication Due to an AE,"An adverse event (AE) was defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it was considered related to the medical treatment or procedure, that occurred during the course of the study.",Up to 52 weeks,,,,,,,,,,,,,,,,,,,Mean Percent Relative Reduction From Baseline in Liver Fat Content (LFC) After 24 Weeks,LFC % was measured by Magnetic Resonance Imaging-Estimated Proton Density Fat Fraction (MRI-PDFF) and evaluated by BICR. MRI-PDFF is a highly accurate noninvasive measure of the proportion of fat content of a tissue.,Baseline and Week 24,Percentage of Participants With ≥1 Stage Improvement in Fibrosis Without Worsening of Steatohepatitis Assessed With the NASH CRN Scoring System After 52 Weeks,"Participants were evaluated with the NASH CRN scoring system with BICR with ≥1 stage improvement in fibrosis without worsening of steatohepatitis defined as no increase in the ballooning, inflammation, or steatosis scores.",Week 52,Percentage of Participants With ≥2 Point Improvement in NAS With ≥1 Point Improvement in Inflammation or Ballooning Without Worsening of Fbrosis by Histology (Evaluated by BICR) After 52 Weeks,Participants with ≥2 point improvement in the NAS with ≥1 point improvement in inflammation or ballooning without worsening of fibrosis were assessed with the NASH CRN scoring system (evaluated by BICR). The NAS was calculated as the unweighted sum of the scores and ranges from 0-8 (highest activity).,Week 52,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
87,Splanchnic and systemic VLDL-TG and FFA balance in individuals with biopsy proven NAFL or NASH,"splanchnic (liver) VLDL-TG and FFA uptake and secretion, in individuals with biopsy proven NAFL or NASH",2 years,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
88,degree of steatosis,degree of steatosis in decibels per meter (dB/m) measured by Controlled Attenuation Parameter (CAP) estimation,12 weeks,,,,,,,,,,,,,,,,,,,,,,,,,degree of steatosis,degree of steatosis in decibels per meter (dB/m) measured by Controlled Attenuation Parameter (CAP) estimation,52 weeks,degree of fibrosis,degree of fibrosis in meter per second (m/s) measured by Acoustic Radiation Force Impulse (ARFI) elastography,12 weeks and 52 weeks,fat mass,fatt mass in kilogram (kg) measured by Bioelectrical Impedance Analysis (BIA),12 weeks and 52 weeks,Glutamate Pyruvate Transaminase (GPT),Glutamate Pyruvate Transaminase in units/litre (U/L),12 weeks and 52 weeks,Gamma-glutamyltransferase (GGT),Gamma-glutamyltransferase in units/litre (U/L),12 weeks and 52 weeks,insulin,insulin in micro units per millilitre (µU/ml),12 weeks and 52 weeks,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
89,Feasibility as measured by adherence to the intervention.,This study is designed to assess the feasibility of a VIIT intervention for adults with NASH-related fibrosis. Adherence will be measured as the % of subjects who are able to achieve the protocol target of 80% of their max heart rate during the intervention.,"Feasibility will be assessed after all subjects have completed the study, after a 12-month recruiting period.",Feasibility as measured by ease of recruiting,This study is designed to assess the feasibility of a VIIT intervention for adults with NASH-related fibrosis. Ease of recruiting will be determined by assessing whether the accrual target was met within the 12-month recruitment timeline.,"Feasibility will be assessed after all subjects have completed the study, after a 12-month recruiting period.",,,,,,,,,,,,,,,,,,,,,,Change in myokine response,The secondary outcome will be the change is 1L-6 and IL-8 cytokine response before and after the intervention.,Secondary outcome measures will be assessed immediately post-exercise and 2-hours following exercise.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
90,Histologic improvements in NAFLD Activity Score (NAS),"The scale used is NAS - this is the NAFLD (Nonalcoholic Fatty Liver Disease) Activity Score.

The NAS was developed to provide a numerical score for patients who most likely have NASH. Accordingly, NAS is the sum of the separate scores for steatosis (0-3), hepatocellular ballooning (0-2) and lobular inflammation (0-3). NAS scores of 0-2 are largely considered not diagnostic of NASH, scores of 3-4 are often considered not diagnostic, borderline, or potentially positive for NASH. Scores of 5-8 are largely considered diagnostic of NASH.

It is expected that the addition of VSG to lifestyle modification will result in more robust histologic improvements in NAFLD Activity Score (NAS) compared to lifestyle modification alone.",Month 12,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
91,Number of subjects that complete at least 50% of the exercise sessions,"The primary study endpoint is feasibility of the use of the application, which is defined as \>50% of subjects adhering to the exercise prescribed, defined as completing \>50% of the sessions.",8 weeks,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
92,To evaluate effects on hepatic histology in patients with NASH,Using the Nonalcoholic fatty liver disease (NAFLD) Activity Score (NAS),13 weeks,,,,,,,,,,,,,,,,,,,,,,,,,Changes in Steatosis on liver biopsy,Graded from 0 to 3,13 weeks,Changes in hepatocellular ballooning score on liver biopsy,Graded from 0 to 2,13 weeks,Changes in inflammation on liver biopsy,Graded from 0 to 3,13 weeks,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
93,Safety outcome,No unexpected treatment related SAEs throughout the participation period and the follow up period,28 weeks,,,,,,,,,,,,,,,,,,,,,,,,,MRI liver fat quantitation,Improvement in MRI fat quantification as determined by a decrease in the fat content by 5% or more from baseline to week 24,Baseline and 24 weeks,ALT levels,Normalization of alanine aminotransferase levels in patients with NASH from baseline to week 24,Baseline and 24 weeks,Liver enzyme improvement,Improvement in liver enzymes by 20% from baseline from baseline to week 24,Baseline and 24 weeks,Lipid profile,Improvement in lipid profile by 20% from baseline from baseline to week 24,Baseline and 24 weeks,HbA1c,Improvement in HBA1c by 0.5 % from baseline from baseline to week 24,Baseline and 24 weeks,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
94,Number of Elafibranor-treated Participants Relative to Placebo Achieving Resolution of Nonalcoholic Steatohepatitis Without Worsening of Fibrosis,To evaluate the effect of Elafibranor compared to placebo on liver histology in nonalcoholic steatohepatitis (NASH) participants with fibrosis by assessing the following endpoint: The number of Elafibranor-treated participants relative to placebo achieving NASH resolution without worsening of fibrosis. This outcome measure is for the surrogate endpoint analysis.,Measurement at 72 weeks,"Time to Long-term Outcome Composed of All-cause Mortality, Cirrhosis, and Liver-related Clinical Outcomes","Composite long-term outcome measured by the number of participants with the onset of any of the adjudicated events, composed of death due to any cause, histological liver cirrhosis, and the full list of portal hypertension/cirrhosis related events as follows: liver transplantation; model for end stage liver disease (MELD) score greater than or equal to 15 for participants with baseline score less than or equal to 12, and onset of variceal bleeding requiring hospitalization, hepatic encephalopathy with West Haven/Conn score greater than or equal to 2 and requiring hospitalization, spontaneous bacterial peritonitis, and ascites requiring treatment. The MELD scale ranges from 6 to 40, showing how much a participant needs a liver transplant: higher number is more urgent. The West Haven/Conn scale is 5-point (0 to 4) grading severity of hepatic encephalopathy: higher score means worse hepatic encephalopathy. This outcome measure is for the long-term endpoint analysis.",From first randomization up to early termination of the study corresponding to 54 months (54 months being the longest duration for any given participant),,,,,,,,,,,,,,,,,,,,,,Number of Elafibranor-treated Participants Relative to Placebo Achieving Improvement of Fibrosis of at Least 1 Stage,"To evaluate the effect of Elafibranor compared to placebo on liver histology in nonalcoholic steatohepatitis (NASH) participants by assessing the following endpoint: The number of Elafibranor-treated participants relative to placebo achieving improvement of liver fibrosis of at least 1 stage according to NASH Clinical Research Network (CRN) Scoring. As the primary efficacy objective was not met, the secondary efficacy endpoints were not formally tested. This outcome measure is for the surrogate endpoint analysis.",Measurements at 72 weeks,Change From Baseline of Hemoglobin A1c (HbA1c) in Diabetic Participants After 72 Weeks of Treatment in Elafibranor-treated Participants Relative to Placebo,"Hemoglobin A1c (HbA1c) were tested at Week 72. Changes from baseline in HbA1c at Week 72 were evaluated. As the primary efficacy objective was not met, the secondary efficacy endpoints were not formally tested. This outcome measure is for the surrogate endpoint analysis.",Measurements after 72 weeks of treatment and up to study termination,Change From Baseline of High-density Lipoprotein (HDL) Cholesterol After 72 Weeks of Treatment in Elafibranor-treated Participants Relative to Placebo,"High-density lipoprotein (HDL) cholesterol was tested at Week 72. Changes from baseline in HDL cholesterol were evaluated at Week 72. As the primary efficacy objective was not met, the secondary efficacy endpoints were not formally tested. This outcome measure is for the surrogate endpoint analysis.",Measurements after 72 weeks of treatment and up to study termination,Change From Baseline of Low-density Lipoprotein (LDL) Cholesterol After 72 Weeks of Treatment in Elafibranor-treated Participants Relative to Placebo,"Low-density lipoprotein (LDL) cholesterol was tested at Week 72. Changes from baseline in LDL cholesterol were evaluated at Week 72. As the primary efficacy objective was not met, the secondary efficacy endpoints were not formally tested. This outcome measure is for the surrogate endpoint analysis.",Measurements after 72 weeks of treatment and up to study termination,Change From Baseline of Homeostatic Model Assessment-IR (HOMA-IR) After 72 Weeks of Treatment in Elafibranor-treated Participants Relative to Placebo in Non-diabetic Participants,"Homeostatic model assessment-IR (HOMA-IR) was tested at Week 72. Changes from baseline in HOMA-IR were evaluated at Week 72. As the primary efficacy objective was not met, the secondary efficacy endpoints were not formally tested. This outcome measure is for the surrogate endpoint analysis.",Measurements after 72 weeks of treatment and up to study termination,Change From Baseline of Non-high Density Lipoprotein Cholesterol After 72 Weeks of Treatment in Elafibranor-treated Participants Relative to Placebo,"Non-high density lipoprotein (HDL) cholesterol was tested at Week 72. Changes from baseline in non-HDL cholesterol were evaluated at Week 72. As the primary efficacy objective was not met, the secondary efficacy endpoints were not formally tested. This outcome measure is for the surrogate endpoint analysis.",Measurements after 72 weeks of treatment and up to study termination,Change From Baseline of Triglycerides After 72 Weeks of Treatment in Elafibranor-treated Participants Relative to Placebo,"Triglycerides was tested at Week 72. Changes from baseline in triglycerides were evaluated at Week 72. As the primary efficacy objective was not met, the secondary efficacy endpoints were not formally tested. This outcome measure is for the surrogate endpoint analysis.",Measurements after 72 weeks of treatment and up to study termination,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
95,Weight change,Assessment of weight before the start of treatment and on the 14th day of treatment. Change will be calculated as a difference from the subtraction of the second measurement from the first.,14 days,Change of satiety level,Assessment of satiety will be performed before the start of treatment and on the 14th day of treatment. Change will be calculated as a difference from the subtraction of the second measurement from the first.,14 days,Change of hunger level,Assessment of hunger will be performed with the use of the hunger scale before the start of treatment and on the 14th day of treatment. Change will be calculated as a difference from the subtraction of the second measurement from the first.,14 days,Presence of adverse events,Assessment of adverse events will be performed before the start of treatment and along the period of treatment.,14 days,Change of proportion of fat in body composition,"Percent of fat in body composition will be assessed with bioelectrical impedance analysis (bioimpedance, BIA). The change will be calculated as a difference from the subtraction of the second measurement from the first.",14 days,Change of proportion of water in body composition,Percent of water in body composition will be assessed with BIA. The change will be calculated as a difference from the subtraction of the second measurement from the first.,14 days,Change of lean body weight,Lean weight in body composition will be assessed with BIA. The change will be calculated as a difference from the subtraction of the second measurement from the first.,14 days,Change in blood docosahexaenoic acid concentration,High performance liquid chromatography with mass spectrometry analysis of blood samples will be performed to evaluate docosahexaenoic acid concentration before the start of medical food product intake and on the last (14th) day of treatment. The change will be calculated as a difference from the subtraction of the second measurement from the first.,14 days,Change in blood hydroxyeycosatetraenoic acid concentration,High performance liquid chromatography with mass spectrometry analysis of blood samples will be performed to evaluate hydroxyeycosatetraenoic acid concentration before the start of medical food product/placebo intake and on the last (14th) day of treatment. The change will be calculated as a difference from the subtraction of the second measurement from the first.,14 days,Change of serum glucose concentration,Blood chemistry will be performed before the start of medical food product/placebo intake and on the last (14th) day of treatment. The change will be calculated as a difference from the subtraction of the second measurement from the first.,14 days,Change of serum insulin concentration,Blood chemistry will be performed before the start of medical food product/placebo intake and on the last (14th) day of treatment. The change will be calculated as a difference from the subtraction of the second measurement from the first.,14 days,Change of serum triglycerides concentration,Blood chemistry will be performed before the start of medical food product/placebo intake and on the last (14th) day of treatment. The change will be calculated as a difference from the subtraction of the second measurement from the first.,14 days,Change of serum high-density lipoprotein concentration,Blood chemistry will be performed before the start of medical food product/placebo intake and on the last (14th) day of treatment. The change will be calculated as a difference from the subtraction of the second measurement from the first.,14 days,Change of serum low-density lipoprotein concentration,Blood chemistry will be performed before the start of medical food product/placebo intake and on the last (14th) day of treatment. The change will be calculated as a difference from the subtraction of the second measurement from the first.,14 days,Change of serum cholesterol concentration,Blood chemistry will be performed before the start of medical food product/placebo intake and on the last (14th) day of treatment. The change will be calculated as a difference from the subtraction of the second measurement from the first.,14 days,Change of serum gamma-glutamine transpeptidase (GGT) activity level,Blood chemistry will be performed before the start of medical food product/placebo intake and on the last (14th) day of treatment. The change will be calculated as a difference from the subtraction of the second measurement from the first.,14 days,Change of serum alanine amino-transferase (AST) activity level,Blood chemistry will be performed before the start of medical food product/placebo intake and on the last (14th) day of treatment. The change will be calculated as a difference from the subtraction of the second measurement from the first.,14 days,Change of serum alanine amino-transferase (ALT) activity,14 days,,,,,,,,,,Blood (serum) ALT level will be measured before the start of the product/placebo intake and on the last (14th) day of treatment by blood chemistry. The change will be calculated as a difference from the subtraction of the second measurement from the first.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Change in concentration of volatile compounds in stool samples,Gas chromatography with mass spectrometry analysis of stool samples obtained before the start of medical food product/placebo intake and on the 14th day of treatment will be performed to evaluate the presence of change in their concentration due to treatment,14 days,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
96,"Proportion of subjects achieving NASH resolution (NAFLD activity score [NAS], ballooning = 0; lobular inflammation = 0, 1) with at least a 2-point reduction in NAS without worsening of fibrosis",,24 weeks,"Proportion of subjects achieving at least 1 stage improvement in liver fibrosis without worsening of NASH (defined as no change in the NAS, ie, the sum score for ballooning, inflammation, and steatosis)",,24 weeks,,,,,,,,,,,,,,,,,,,,,,Proportion of subjects achieving the composite of both NASH resolution and at least 1 stage improvement of liver fibrosis at 24 weeks,,24 weeks,Relative change (%) in liver fat content by MRI-PDFF,,24 weeks and 48 weeks,Absolute change in MRI-based corrected T1 (cT1) imaging,,24 weeks and 48 weeks,Absolute change in alanine aminotransferase (ALT),,24 weeks and 48 weeks,Absolute change in Enhanced Liver Fibrosis (ELF) score,,24 weeks and 48 weeks,Absolute change in Fibroscan-AST (FAST) score,,24 weeks and 48 weeks,Relative (%) change in body weight,,24 weeks and 48 weeks,"Absolute changes in fasting lipids (total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides)",,24 weeks and 48 weeks,Change in HbA1c (%),24 weeks and 48 weeks,Change in glucose (mg/dL),24 weeks and 48 weeks,Change in systolic and diastolic blood pressure (mmHg),,24 weeks and 48 weeks,Change in heart rate (beats per minute),24 weeks and 48 weeks,The number of subjects with treatment emergent adverse events,48 weeks,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
97,Clinically significant liver fat loss,Proportion of participants achieving \>30% relative reduction in MRI-PDFF after Wk. 16.,16 weeks,,,,,,,,,,,,,,,,,,,,,,,,,Sustained clinically significant body weight loss,Proportion of participants achieving \>5% body weight loss after Wk. 16.,16 weeks,Sustained clinically significant body weight loss,Proportion of participants achieving \>5% body weight loss after Wk. 48.,48 weeks,Liver fat and liver stiffness using imaging analysis,• VCTE will assess change in liver fat and stiffness at Wks. 16,16 weeks,Liver fat and liver stiffness using imaging analysis,• MRI-PDFF will assess change in liver fat at Wks. 16,16 weeks,Liver fat and liver stiffness using imaging analysis,• MRE will assess change in liver stiffness at Wks. 16,16 weeks,Liver fat and liver stiffness using imaging analysis,• VCTE will assess change in liver fat and stiffness at Wks. 48.,48 weeks,Liver fat and liver stiffness using imaging analysis,• MRI-PDFF will assess change in liver fat at Wks. 48.,48 weeks,Liver fat and liver stiffness using imaging analysis,• MRE will assess change in liver stiffness at Wks. 48,48 weeks,Clinically meaningful improvement in liver fat and stiffness,16 weeks,Clinically meaningful improvement in liver fat and stiffness,16 weeks,Clinically meaningful improvement in liver fat and stiffness,• Proportion of participants with \>15% decrease in MRE-measured liver stiffness (kPA) after Wks. 16,16 weeks,Clinically meaningful improvement in liver fat and stiffness,48 weeks,Clinically meaningful improvement in liver fat and stiffness,48 weeks,• Proportion of participants with \>26% relative reduction in VCTE-measured liver stiffness (kPA) after Wks. 16,Clinically meaningful improvement in liver fat and stiffness,48 weeks,• Proportion of participants with \>30% relative reduction in MRI-PDFF after Wk. 16,• Proportion of participants with \>26% relative reduction in VCTE-measured liver stiffness (kPA) after Wks. 48.,• Proportion of participants with \>30% relative reduction in MRI-PDFF after Wk. 48.,• Proportion of participants with \>15% decrease in MRE-measured liver stiffness (kPA) after Wks.48,Circulating biomarkers of hepatic injury,• Change in ALT after Wks. 16,16 Weeks,Circulating biomarkers of hepatic injury,• Proportion of participants with \>17 IU/L decrease in ALT96 after Wks. 16,16 Weeks,Circulating biomarkers of hepatic injury,• Change in AST after Wks. 16,16 Weeks,Circulating biomarkers of hepatic injury,• Change in CK-18 after Wks. 16,16 Weeks,Circulating biomarkers of hepatic injury,• Change in GGT after Wks. 16,16 Weeks,Circulating biomarkers of hepatic injury,• Change in NASH Fibrotic Index after Wks. 16,16 Weeks,Circulating biomarkers of hepatic injury,• Proportion of participants with \>17 IU/L decrease in ALT96 after Wks. 16.,16 Weeks,Circulating biomarkers of hepatic injury,• Change in ALT after Wks. 48.,48 weeks,Circulating biomarkers of hepatic injury,• Change in AST after Wks. 48.,48 weeks,Circulating biomarkers of hepatic injury,• Change in CK-18 after Wks. 48.,48 weeks,Circulating biomarkers of hepatic injury,• Change in GGT after Wks. 48.,48 weeks,Circulating biomarkers of hepatic injury,• Change in NASH Fibrotic Index after Wks. 48.,48 weeks,Circulating biomarkers of hepatic injury,• Proportion of participants with \>17 IU/L decrease in ALT96 after Wks. 48.,48 weeks,Circulating biomarkers of liver fibrosis and fibrogenesis,• Change in Enhanced Liver Fibrosis (ELF) score after Wks. 16,16 Weeks,Circulating biomarkers of liver fibrosis and fibrogenesis,• Change in Fibrosis-4 index (FIB-4) after Wks. 16,16 Weeks,Circulating biomarkers of liver fibrosis and fibrogenesis,• Change in PRO-C3 after Wks. 16,16 Weeks,Circulating biomarkers of liver fibrosis and fibrogenesis,• Change in Enhanced Liver Fibrosis (ELF) score after Wks. 48.,48 weeks,Circulating biomarkers of liver fibrosis and fibrogenesis,• Change in Fibrosis-4 index (FIB-4) after Wks. 48.,48 weeks,Circulating biomarkers of liver fibrosis and fibrogenesis,• Change in PRO-C3 after Wks. 48.,48 weeks,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
98,Improvement in Nonalcoholic fatty liver disease activity score (NAS) by 2 points,"To examine the efficacy of daily low dose Synthroid, using a dose-titration strategy based on serum thyroid stimulating hormone (TSH), on the histological progression of nonalcoholic steatohepatitis (NASH) in Veterans with normal serum TSH levels and biopsy-proven NASH, and to compare the treated patients with Veterans on placebo. Liver biopsies will be obtained at baseline (Week 0) and at end of treatment (Week 52). Nonalcoholic fatty liver disease activity score (NAS) will be assessed in baseline and post treatment liver biopsies and improvement in NAS will be compared between study group on active treatment and placebo group.",12 months,,,,,,,,,,,,,,,,,,,,,,,,,Proportion of subjects experiencing improvement in biopsy-determined fibrosis by at least one stage,The stage of liver fibrosis will be assessed in the study subjects at baseline and post intervention. Improvement in the stage of fibrosis will be compared between the placebo and study groups.,12 months,Improvement in mitochondrial fatty acid oxidation,Effect of Synthroid on mitochondrial fatty acid oxidation will be assessed by measurement of complete mitochondrial fatty acid oxidation in liver tissue obtained at baseline and post intervention (52 weeks) in study and placebo groups.,12 months,Improvement in mitochondrial biogenesis,Effect of Synthroid on mitochondrial biogenesis will be assessed by measurement of PCG-1alpha (peroxisome-proliferator-activated receptor gamma coactivator 1 alpha) gene expression in the liver tissue at baseline and post intervention at 52 weeks in the study and placebo groups.,12 months,Improvement in mitochondrial mitophagy,Effect of Synthroid on mitochondrial mitophagy will be assessed by measurement of BNIP3 (BCL2 interacting protein 3) gene expression in the liver tissue at baseline and post intervention at 52 weeks in the study and placebo groups.,12 months,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
99,Establish an understanding of the current natural history of NASH at academic and community medical centers,"A detailed analysis of demographics, concurrent medications, metabolic and cardiovascular co-morbidities, staging of liver disease, and outcomes for patients with NASH managed in diverse clinical settings will serve as an important comparator for subsequent interventions that alter the treatment paradigm for this disease.",10 years,Evaluate NASH treatment regimens being used in clinical practice,"Currently, there are no FDA approved therapies for NASH, however clinicians may use a variety of interventions including diet and exercise programs, vitamin E, bariatric surgery or other unapproved uses of some cholesterol, lipid lowering, anti-diabetic and anti-inflammatory medications as well as alternative medications. TARGET-NASH will monitor the safety and effectiveness of the various treatment choices in enrolled patients.",10 years,Examine populations underrepresented in phase II-III clinical trials,"Patients with cirrhosis, age \> 70, patients who consume moderate amounts of alcohol and patients with multiple comorbidities such as severe depression, chronic fatigue, fibromyalgia, type 2 diabetes, inflammatory bowel disease, or cardiovascular disease.",10 years,Evaluate optimal duration and combination of NASH therapies to achieve clinical response and clinical remission,"In addition to diet and exercise, type, dose and duration of therapy of each NASH treatment (both current unapproved therapies and future FDA approved drugs) will be closely followed, with a goal to monitor treatment paradigms and various combination regimens for clinical response and clinical remission.",10 years,Examine liver histology,,10 years,Estimate adverse event frequency and severity and describe management practices,"NASH can often be an asymptomatic disease in the setting of other disease-related comorbidities such as diabetes and cardiovascular disease. Once NASH progresses to cirrhosis, these patients can suffer the attendant complications of decompensated liver disease including debilitating fatigue, muscle wasting, ascites, bleeding, encephalopathy, hepatocellular carcinoma, and death. NASH therapies may increase the frequency and severity of certain adverse events, such as edema (pioglitazone), some cancers (vitamin E), and new agents or combinations of agents may have their own unique adverse event profiles and varying needs for management plans (e.g., pruritus and dyslipidemia).",10 years,Evaluate the impact of NASH therapies on medical co-morbidities,,10 years,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
